Non-naturally occurring melanocortin analogs and their use for treating substance use disorders

Abstract

This article provides methods for treating, preventing, reducing, or otherwise improving substance use disorders in subjects in need, comprising administering to the subject a non-naturally occurring melanocorticoid analogue. In some embodiments, the substance use disorder includes alcohol use disorder or opioid substance use disorder.

Description

Cross-references to related applications

[0001] This application claims the benefit of the following U.S. provisional patent applications: U.S. Provisional Patent Application No. 63 / 607,500, filed December 7, 2023; U.S. Provisional Patent Application No. 63 / 618,843, filed January 8, 2024; U.S. Provisional Patent Application No. 63 / 557,385, filed February 23, 2024; U.S. Provisional Patent Application No. 63 / 573,429, filed April 2, 2024; U.S. Provisional Patent Application No. 63 / 650,705, filed May 22, 2024; U.S. Provisional Patent Application No. 63 / 656,583, filed June 5, 2025; and U.S. Provisional Patent Application No. 63 / 663,648, filed June 24, 2024, all of which are incorporated herein by reference in their entirety.

[0002] Incorporate into the sequence list by reference This application contains a sequence list conforming to ST.26, which is submitted concurrently in XML format and incorporated herein by reference in its entirety. This .xml copy was created on December 9, 2024, is named “146316_8017_WO02_SL.xml”, and has a size of 1,472,360 bytes. Background Technology

[0003] Opioid receptors (such as μ-opioid receptors and delta-opioid receptors) are the primary molecular targets for pain management. The vast majority of pain medications prescribed clinically are opioid receptor ligands (i.e., opioid drugs), which are structurally similar to or derived from morphine or other opioid preparations. While these drugs provide effective pain relief, their use can lead to undesirable side effects, including increased tolerance, addiction, overdose, difficulty breathing, and constipation.

[0004] Opioid and other substance addictions, such as alcohol and nicotine addictions, cause millions of premature deaths each year. Although current therapies designed to treat addiction may be effective, many substance users are unable to overcome their addiction despite their desire to quit.

[0005] Even with recent advances in pain medication development, there remains a significant need for new drugs that offer improved therapeutic characteristics (e.g., potent therapeutic activity and reduced unwanted adverse side effects) compared to conventional opioid medications to manage pain. The demand for new therapies for opioid use disorders (i.e., opioid addiction) and other addictions (such as alcohol use disorders and nicotine addiction) continues to grow. Summary of the Invention

[0006] This technology includes methods for alleviating substance use disorders and / or pain in subjects in need, methods including administering a non-natural melanocorticoid analogue to the subject.

[0007] In some implementations, the technology includes a method for reducing pain levels in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog of formula (I): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, d Lys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is the group that is absent or selected from the following: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H). - Ketone (Ata), 4-amino-1,4,5,6-tetrahydroazapyro[4,3-b]indole-3(2H)-ketone (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip);R4 is selected from the following groups: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the following groups: Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups. : Gly, Pro, Lys, dLys, Cys, dCys, Penicillamine (Pen), dPen, and Orn; R8 indicates absence or Lys; Y1 indicates absence or selection from the following groups: Valine (Val), D-Valine (dVal), β2-Valine (b2-Val), β3-Valine (b3-Val), Pro, D-Proline (dPro), β-Proline (b-Pro), Hyp, D-Hypine (dHyp), D-Tertiary-Leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn) Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y8, Y9, Y1, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y4, Y1, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y4, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y3, Y4, Y1, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y3, Y4, Y1, Y2 ... The non-natural melanocortin analogue is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 is independently selected from the group consisting of Cys, dCys and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro;When R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, R6 is Trp, and the non-natural melanocortin analog is not cyclized between Cys at R2 and Cys at R7, or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, the non-natural melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or does not exist, (ii) R3 is His, and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 do not exist simultaneously, or (iv) R3 does not exist and R2 and R7 are not both dPen; when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized via a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 exists or Y3 exists; and when R2 is dAla, then R4 is dPhe and Y1-Y7 are absent.

[0008] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing pain levels in a subject in need relative to a control, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0009] In some implementations, the technology includes a method for treating, preventing, or reducing addiction in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0010] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the treatment, prevention, or reduction of addiction in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0011] In some implementations, the technology includes a method for preventing or reducing a subject’s use of or dependence on an addictive substance relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0012] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of a subject’s use or dependence on an addictive substance relative to a control treatment, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0013] In some implementations, the technology includes a method for treating or preventing opioid use disorder (OUD) in a subject in need of control therapy or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0014] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of OUD in a subject in need of control therapy or prevention, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0015] In some implementations, the technology includes a method for treating or preventing alcohol use disorder (AUD) in a subject in need of control treatment or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0016] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of AUD in a subject in need of a control or preventative treatment, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0017] In some implementations, the method or use includes reducing the dosage of the addictive substance used or consumed relative to a control.

[0018] In some implementations, the method or use includes reducing dependence on addictive substances relative to a control.

[0019] In some implementations, the method or use includes reducing the frequency of use of addictive substances relative to a control.

[0020] In some implementations, the method or use includes reducing the dose or dosage of a conventional drug used to treat addiction relative to a control.

[0021] In some implementations, the technology includes a method for enhancing the effect of a conventional drug used to treat addiction in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0022] In some embodiments, the technology includes the use of a non-naturally occurring melanocorticoid analogue to enhance the effects of a conventional drug used to treat addiction in a subject in need, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0023] In some implementations, the technology includes a method for reducing or eliminating, relative to a control, the need of a subject for conventional drugs used to treat addiction, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0024] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing or eliminating the need of a subject in need of a conventional drug for treating addiction, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0025] In some implementations, treatment of addiction is improved during or after the administration of this non-natural melanocorticoid analogue compared to treatment of addiction using conventional drugs alone for treating addiction.

[0026] In some implementations, conventional drugs for treating addiction are selected from the group consisting of: buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-α-acetylmethadone (LAAM), codeine, lofexidine, and sustained-release morphine.

[0027] In some implementations, the technology includes a method for reducing hospitalization or rehabilitation needs associated with addiction or use of addictive substances relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0028] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0029] In some implementations, the technology includes a method for preventing or mitigating withdrawal symptoms of an addictive substance in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0030] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of withdrawal symptoms of an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0031] In some implementations, the technology includes a method for preventing or alleviating symptoms associated with withdrawal of an addictive substance in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0032] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of symptoms associated with withdrawal from addictive substances in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0033] In some implementation schemes, symptoms associated with withdrawal from addictive substances are selected from the following groups: pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle pain, nausea, sleep problems, suicidal ideation, tremor, and visual impairment.

[0034] In some implementation schemes, the subjects are addicted to or prone to addiction to addictive substances.

[0035] In some implementations, the subject has used or is currently using one or more addictive substances.

[0036] In some implementations, this technology includes a method or use in which addictive substances include prescription drugs, substances in over-the-counter drugs, recreational substances, or illicit substances.

[0037] In some implementations, the addictive substance is selected from the group consisting of: opioids, analgesics, stimulants, narcotics, alcohol, sedatives, marijuana, cannabis products, tetrahydrocannabinol (THC), cannabidiol (CBD), and inhalants.

[0038] In some implementations, the opioid substance is selected from the group consisting of: morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0039] In some implementations, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamine, cocaine, and amphetamine.

[0040] In some implementations, the sedative includes barbiturates or benzodiazepines.

[0041] In some implementations, the barbiturates are selected from the group consisting of: phenobarbital, mesobarbital, buprofen, pentobarbital, primidone, and amobarbital.

[0042] In some implementations, benzodiazepines are selected from the group consisting of: alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0043] In some implementations, the sedative is selected from the group consisting of: tranquilizer, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0044] In some implementations, the inhalant is selected from the group consisting of: aerosols, butane, Freon, helium, nitrous oxide, propane, and nitrite.

[0045] In some implementations, nicotine includes tobacco chewing products, nicotine pouches, or smoking devices.

[0046] In some implementations, the smoking device is selected from the group consisting of: cigarettes, electronic cigarettes, cigars, and electronic cigarette products.

[0047] In some implementations, the control group includes the subject prior to administration of the non-naturally occurring melanocorticoid analogue.

[0048] In some implementations, the control group includes the subject at baseline.

[0049] In some implementations, the non-natural melanocortin analogue is a melanocortin 4 receptor (MC4R) agonist.

[0050] In some implementations, the MC4R agonist is a full-type MC4R agonist.

[0051] In some implementations, the MC4R agonist is a partial MC4R agonist.

[0052] In some implementations, non-natural melanocortin analogs are MC3R antagonists.

[0053] In some implementations, the MC3R antagonist is a full-type MC3R antagonist.

[0054] In some implementations, the MC3R agonist is a partial MC3R agonist.

[0055] In some implementations, non-natural melanocortin analogs do not have MC3R activity.

[0056] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence according to formula (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. The following are the groups selected for R2: Acid (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is either absent or selected from the group consisting of: His, Ala, Pr o, Hydroxyproline (Hyp), Leucine (Leu), D-Glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-Amino-1,2,4,5-Tetrahydro-2-benzozaza-3-one (Aba), 7-Amino-7,8-Dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-Amino-1,4,5,6-Tetrahydrozazaza-[4,3-b]indol-3(2H)-one (Aia), 2-Aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-Amino-4-phenylcyclohexane-carboxylic acid (APC), 4-Aminophenylpiperidine-4-carboxylic acid (AP) PC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan);R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg. Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen. The disulfide bond between R1 or R2 and R7 or R8; the disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO:10);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9);Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12);Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15);Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18);Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20);Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21);Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24);Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28);Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 29);Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 30);dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35);Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 43);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64);Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68);Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 69);Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:76);Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 119);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2 (SEQID NO: 124);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2 (SEQ ID NO:125);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 130);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQID NO: 132);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 135);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 143);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ IDNO: 144);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 150);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 153);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO:154);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 155);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 161);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 162);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2 (SEQ ID NO: 169);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 170);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2(SEQ ID NO: 174);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 175);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 176);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2 (SEQ IDNO: 177);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO:178);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:179);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:180);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 181);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQID NO: 182);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183);Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184);Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185);Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Tr-Lys-Pro-DNL(2') NO: 186);Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTr-SE-DN-dNal(2') NO: 196);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 203);Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dNal-dNal(2') ID: NO 204);Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205);Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-d SEQ-dNal(2') IDH: 206);Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 240);Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-d Pro-DNVal(2')-IDNO NO:241);Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242);Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys-dNal(2')-Arg-Trp-Lys-d-Pro-IDH2: 244);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245);Ac-Nle-c[Asp-His-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cis-Pro(guan)Pro-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 251); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 253); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH₂ (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 261); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 273);Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:274);Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:275);Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:327);Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:328);Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:329);Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330);Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331);Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332);Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 333);Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334);Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335);Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336);Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2 (SEQ ID NO: 349);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2 (SEQ ID NO: 350);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103);Ac-Nle-c[Asp-Ioc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 46);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ IDNO: 56);Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62);Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83);Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338);Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 339);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ IDNO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:225);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514);Ac-Nle-c[Asp-dGln-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH₂ (SEQ ID NO: 269); Ac-dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 270); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH₂ (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-NH₂ (SEQ ID NO: 283).;

[0057] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence according to formula (IA): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4 (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His. dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTy R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is the group selected from the following: dPhe, p-Chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, β2-Val, β3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is... The following groups are absent or selected: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the following groups: dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analogue is partially cyclized by the following groups: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, R6 is Trp, and the non-natural melanocortin analogue is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analogue is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, the non-natural melanocortin analogue is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7;When R4 is dPhe, then (i) R3 is not His, Pro, or does not exist; (ii) R3 is His and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg; (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 do not exist simultaneously, or (iv) R3 does not exist and R2 and R7 are not both dPen; and when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized via a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 or Y3 exists.

[0058] In some embodiments, the non-naturally occurring melanocortin analogue comprises a sequence according to formula (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla). Arg, dArg, Lys, dLys, His, dHis, Ornithine (Orn), D-Ornithine (dOrn), D-Leucine (dLeu), D-Tyrosine (dTyr), Phenylalanine (Phe), D-Phenylalanine (dPhe), Tryptophan (Trp), D-Tryptophan (dTrp), Aspartic acid (Asp), Cysteine ​​(Cys), and D-Cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, H is, dHis, Tyr, and dTyr; R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the following: Groups: dPhe, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp Y1 consists of asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 consists of the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dThr, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 consists of the following groups: Val, dVal, Pro, and dPr. o, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; and the non-natural melanocortin analogue is partially cyclized by selecting from the group consisting of: the disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; the disulfide bond between R2 and R7 or R8 when R2 is Cys, R7 is Pen, and R3 is absent. The disulfide bond between R1 or R2; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:380);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);and Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 514).;

[0059] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB): X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7(IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys). R1 is histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cis-Pro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-Asparagine (dAsn) and D-Threonine (dThr); Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys and dLys;Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, the non-naturally occurring melanocortin analogue is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1, X2, and X3 are present, then Y3-Y7 are absent.

[0060] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB), wherein: X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D -Phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'- Naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, L Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys.Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analogue does not contain the following sequence: Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639). ;

[0061] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (IC): X1-X2-R1-R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), where: X1 is selected from the following groups: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the following groups: aspartic acid (Asp), cysteine ​​(Cys) and D-cysteine ​​(dCys); R2 is selected from the following groups: tryptophan (Trp), phenylalanine (Phe), D-phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr) and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the following groups: Trp, 2'-D-naphthylalanine (dNal(2')), 2 '-Naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys and dCys; Y1 is absent or selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg and dLys; Y2 is absent or selected from the group consisting of dVal, dPro and D-hydroxyproline (dHyp); Y3 is absent, dVal or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R1 and R7 when both R1 and R7 are independently selected from the group consisting of Cys, dCys and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys; In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (ID): X1-R1-R2-R3-p(Cl)dPhe-Arg-Trp-R7-Y1-Y2-Y3-Y4 (ID), where: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His) and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata) and 4-amino-1,4,5,6-tetrahydroazaza-[4, [3-b] Indole-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and this non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1Y2 is dVal-dPro, X1 is absent, and the non-natural melanocortin analogue is cyclized by disulfide bonds, or (b) Y1Y2 is not dVal-dPro and either X1 or Y3 is present.

[0062] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (ID), wherein: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid. (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), and 4-amino-1,4,5,6-tetrahydrozazaza[4,3-b]indole-3 ( 2H)-keto (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of: D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of: dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-natural melanocortin analogue does not contain a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); and.

[0063] In some implementations, the N-terminus of a non-natural melanocortin analog is modified with an acyl group.

[0064] In some implementations, the acyl group is an acetyl group.

[0065] In some implementations, the N-terminus of non-naturally occurring melanocortin analogues is not modified.

[0066] In some implementations, the C-terminus of a non-natural melanocortin analog is modified with an amide group.

[0067] In some implementations, the C-terminus of the non-natural melanocortin analogue is not modified.

[0068] In some implementations, Y1-Y2 exist, while Y3-Y8 do not.

[0069] In some implementations, Y1 is D-valine and Y2 is D-proline.

[0070] In some embodiments, the technology includes a method or use in which Y1 is D-tert-leucine and Y2 is D-proline.

[0071] In some implementations, R4 is dNal(2').

[0072] In some embodiments, the sequence of formula (I) is: Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), where c represents cyclization via lactam bonds through R2 and R8.

[0073] In some implementations, R4 is Phe or dPhe.

[0074] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296), where c represents cyclization via a lactam bond through R2 and R7.

[0075] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300). 301); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); NO: 310); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311);Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), where c represents cyclization via lactam bonds through R2 and R7.

[0076] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac-Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 319). 321); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 324), where c represents cyclization via disulfide bonds through R2 and R7.

[0077] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 353), where c represents cyclization via lactam bonds through R2 and R8.

[0078] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle-c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355). 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-Ioc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle-c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 373);Ac-Nle-c[Asp-Tyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 214), where c represents cyclization via lactam bonds through R2 and R7.

[0079] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), where c represents cyclization via lactam bonds through R1 and R7.

[0080] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 384). 385); Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp-Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 394);Ac-Nle-c[Asp-Trp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:395);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1']-Lys]-dVal-dPro-NH2 (SEQ ID NO:399);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:403);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:404);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO:405);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO:406);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411);Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 412);Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413);Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), where c represents cyclization via a lactam bond or disulfide bond through R1 and R7.

[0081] In some embodiments, the sequence of any of formulas (I)-(ID) is: Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), where c represents cyclization via lactam bonds through R2 and R8.

[0082] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 421); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 423). 424), where c represents cyclization via lactam bonds through R1 and R7.

[0083] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233). 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 429), where c represents cyclization via lactam bonds through R2 and R7.

[0084] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 434); 435); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 446);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQID NO: 447);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 448);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:449);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:450);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 451);Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:452);Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 453);Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454);Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455);Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456);Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457);Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458);Ac-Nle-c[Cys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 461); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), where c represents cyclization via a lactam bond or a disulfide bond through R2 and R7.

[0085] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211). 499); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 523), where c represents cyclization via a lactam bond or disulfide bond through R2 and R7.

[0086] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), where c represents cyclization via disulfide bonds through R2 and R7.

[0087] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 5775 ... 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 581); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 587);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ IDNO: 594);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:595);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 599);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ 602);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 603);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID 604);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dQNOH2 (Asp-NHal 606);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 607);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 ( 608);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH: NOH2 ( 610);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn:IDPro-NH 612);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID 614);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ IDNO: 620); Ac-Nle-c[dAsp-Pro-dPhe-Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β2Val-βPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β3Val-βPro-NH2 (SEQ ID NO: 626); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-βPro-NH2 (SEQ ID NO: 627), where c represents cyclization via lactam bonds through R2 and R7.

[0088] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), where c represents cyclization via lactam bond through R2 and R7.

[0089] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 633). 634); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645);And Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), where c represents cyclization via lactam bonds through R2 and R7.

[0090] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0091] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 212, 218, 226, 291, 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-598, 600-646.

[0092] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 218, 231-235, 291, 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0093] In some implementations, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 226, 383-393, 399, 403-417.

[0094] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 209-211, 499, 501-506, 511-513, 515, 518-523.

[0095] In some implementations, a non-natural melanocortin analogue is present in the pharmaceutical composition.

[0096] In some embodiments, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and / or carriers.

[0097] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0098] In some embodiments, the non-natural melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 5 mg / kg to about 20 mg / kg for about 5 to about 10 days; (ii) once daily at a second dose of about 10 mg / kg to about 40 mg / kg after the first dose for about 5 to about 10 days; and (iii) twice daily at a third dose of about 5 mg / kg to about 30 mg / kg after the second dose for at least about 5 to about 10 days.

[0099] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 5 mg / kg once a day for about 7 days; (ii) a second dose of about 15 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 10 mg / kg twice a day for at least about 7 days after the second dose.

[0100] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 10 mg / kg once a day for about 7 days; (ii) a second dose of about 20 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 15 mg / kg twice a day for at least about 7 days after the second dose.

[0101] In some embodiments, the technology includes a method or use in which the non-naturally occurring melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 15 mg / kg for about 7 days; (ii) once daily at a second dose of about 25 mg / kg after the first dose for about 7 days; and (iii) twice daily at a third dose of about 20 mg / kg after the second dose for at least about 7 days.

[0102] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 0.5 mg / kg to about 10 mg / kg based on the subject's body weight.

[0103] In some implementations, non-natural melanocorticoid analogues are administered once daily at a dose of about 1 mg / kg or 3 mg / kg based on the subject's body weight.

[0104] In some implementations, non-natural melanocorticoid analogues are administered once daily at doses of about 0.1 mg to about 100 mg.

[0105] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 10 mg or about 50 mg.

[0106] In some implementations, non-natural melanocorticoid analogues are administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

[0107] In some implementations, non-natural melanocortin analogs cross the blood-brain barrier in the subject.

[0108] In some implementations, the non-naturally occurring melanocortin analogue contains SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646, any one of the sequences, and at a dose of 0.001 mg / kg to 25 mg / kg based on the subject's body weight. Administer at least once daily at doses within the mg / kg range.

[0109] In some implementations, non-naturally occurring melanocortin analogues include SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429. The drug is administered at least once daily in any of the sequences 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, and 622-646, at a dose ranging from 0.5 mg / kg to 10 mg / kg based on the subject's body weight.

[0110] In some implementations, non-natural melanocorticoid analogs are administered to subjects for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0111] In some implementations, non-natural melanocortin analogues are administered to subjects for 1, 5, 7, 14, 21, 28, 35, 40, 45, 50, 60, 75, 90, 100, 110, or 120 days.

[0112] In some implementations, the technology includes a method for reducing pain levels in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog of formula (I): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, d Lys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is the group that is absent or selected from the following: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H). - Ketone (Ata), 4-amino-1,4,5,6-tetrahydroazapyro[4,3-b]indole-3(2H)-ketone (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip);R4 is selected from the following groups: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the following groups: Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups. : Gly, Pro, Lys, dLys, Cys, dCys, Penicillamine (Pen), dPen, and Orn; R8 indicates absence or Lys; Y1 indicates absence or selection from the following groups: Valine (Val), D-Valine (dVal), β2-Valine (b2-Val), β3-Valine (b3-Val), Pro, D-Proline (dPro), β-Proline (b-Pro), Hyp, D-Hypine (dHyp), D-Tertiary-Leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn) Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y8, Y9, Y1, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y4, Y1, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y4, Y1, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y1, Y2, Y3, Y1, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y3, Y4, Y1, Y1, Y2, Y1, Y2, Y3, Y1, Y2, Y3, Y4, Y1, Y2 ... The non-natural melanocortin analogue is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: a disulfide bond between R1 or R2 and R7 when each of R1 or R2 and R7 is independently selected from the group consisting of Cys, dCys and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro;When R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, R6 is Trp, and the non-natural melanocortin analog is not cyclized between Cys at R2 and Cys at R7, or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analog is cyclized through a disulfide bond between R2 and R7; when R4 is p(Br)dPhe, the non-natural melanocortin analog is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7; when R4 is dPhe, then (i) R3 is not His, Pro, or does not exist, (ii) R3 is His, and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg, (iii) R3 is Pro and (a) R2 is Trp and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 do not exist simultaneously, or (iv) R3 does not exist and R2 and R7 are not both dPen; when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized via a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 exists or Y3 exists; and when R2 is dAla, then R4 is dPhe and Y1-Y7 are absent.

[0113] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing pain levels in a subject in need relative to a control, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0114] In some implementations, the technology includes a method for treating, preventing, or reducing addiction in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0115] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the treatment, prevention, or reduction of addiction in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0116] In some implementations, the technology includes a method for preventing or reducing a subject’s use of or dependence on an addictive substance relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0117] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of a subject’s use or dependence on an addictive substance relative to a control treatment, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0118] In some implementations, the technology includes a method for treating or preventing opioid use disorder (OUD) in a subject in need of control therapy or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0119] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of OUD in a subject in need of control therapy or prevention, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0120] In some implementations, the technology includes a method for treating or preventing alcohol use disorder (AUD) in a subject in need of control treatment or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0121] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of AUD in a subject in need of a control or preventative treatment, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0122] In some implementations, the method or use includes reducing the dosage of the addictive substance used or consumed relative to a control.

[0123] In some implementations, the method or use includes reducing dependence on addictive substances relative to a control.

[0124] In some implementations, the method or use includes reducing the frequency of use of addictive substances relative to a control.

[0125] In some implementations, the method or use includes reducing the dose or amount of a conventional drug used to treat addiction relative to a control.

[0126] In some implementations, the technology includes a method for enhancing the effect of a conventional drug used to treat addiction in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0127] In some embodiments, the technology includes the use of a non-naturally occurring melanocorticoid analogue to enhance the effects of a conventional drug used to treat addiction in a subject in need, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0128] In some implementations, the technology includes a method for reducing or eliminating, relative to a control, the need of a subject for conventional drugs used to treat addiction, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0129] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing or eliminating the need of a subject in need of a conventional drug for treating addiction, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0130] In some implementations, treatment of addiction is improved during or after the administration of this non-natural melanocorticoid analogue compared to treatment of addiction using conventional drugs alone for treating addiction.

[0131] In some implementations, conventional drugs for treating addiction are selected from the group consisting of: buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-α-acetylmethadone (LAAM), codeine, lofexidine, and sustained-release morphine.

[0132] In some implementations, the technology includes a method for reducing hospitalization or rehabilitation needs associated with addiction or use of addictive substances relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0133] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0134] In some implementations, the technology includes a method for preventing or mitigating withdrawal symptoms of an addictive substance in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0135] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of withdrawal symptoms of an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0136] In some implementations, the technology includes a method for preventing or alleviating symptoms associated with withdrawal of an addictive substance in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0137] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of symptoms associated with withdrawal from addictive substances in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0138] In some implementation schemes, symptoms associated with withdrawal from addictive substances are selected from the following groups: pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle pain, nausea, sleep problems, suicidal ideation, tremor, and visual impairment.

[0139] In some implementation schemes, the subjects are addicted to or prone to addiction to addictive substances.

[0140] In some implementations, the subject has used or is currently using one or more addictive substances.

[0141] In some implementations, this technology includes a method or use in which addictive substances include prescription drugs, substances in over-the-counter drugs, recreational substances, or illicit substances.

[0142] In some implementations, the addictive substance is selected from the group consisting of: opioids, analgesics, stimulants, narcotics, alcohol, sedatives, marijuana, cannabis products, tetrahydrocannabinol (THC), cannabidiol (CBD), and inhalants.

[0143] In some implementations, the opioid substance is selected from the group consisting of: morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0144] In some implementations, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamine, cocaine, and amphetamine.

[0145] In some implementations, the sedative includes barbiturates or benzodiazepines.

[0146] In some implementations, the barbiturates are selected from the group consisting of: phenobarbital, mesobarbital, buprofen, pentobarbital, primidone, and amobarbital.

[0147] In some implementation schemes, benzodiazepines are selected from the group consisting of: alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0148] In some implementations, the sedative is selected from the group consisting of: diazepam, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0149] In some implementations, the inhalant is selected from the group consisting of: aerosols, butane, Freon, helium, nitrous oxide, propane, and nitrite.

[0150] In some implementations, nicotine includes tobacco chewing products, nicotine pouches, or smoking devices.

[0151] In some implementations, the smoking device is selected from the group consisting of: cigarettes, electronic cigarettes, cigars, and electronic cigarette products.

[0152] In some implementations, the control group includes the subject prior to administration of the non-naturally occurring melanocorticoid analogue.

[0153] In some implementations, the control group includes the subject at baseline.

[0154] In some implementations, the non-natural melanocortin analogue is a melanocortin 4 receptor (MC4R) agonist.

[0155] In some implementations, the MC4R agonist is a full-type MC4R agonist.

[0156] In some implementations, the MC4R agonist is a partial MC4R agonist.

[0157] In some implementations, non-natural melanocortin analogs are MC3R antagonists.

[0158] In some implementations, the MC3R antagonist is a full-type MC3R antagonist.

[0159] In some implementations, the MC3R agonist is a partial MC3R agonist.

[0160] In some implementations, non-natural melanocortin analogs do not have MC3R activity.

[0161] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence according to formula (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. The following are the groups selected for R2: Acid (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is either absent or selected from the group consisting of: His, Ala, Pr o, Hydroxyproline (Hyp), Leucine (Leu), D-Glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-Amino-1,2,4,5-Tetrahydro-2-benzozaza-3-one (Aba), 7-Amino-7,8-Dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-Amino-1,4,5,6-Tetrahydrozazaza-[4,3-b]indol-3(2H)-one (Aia), 2-Aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-Amino-4-phenylcyclohexane-carboxylic acid (APC), 4-Aminophenylpiperidine-4-carboxylic acid (AP) PC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan);R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg. Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen. The disulfide bond between R1 or R2 and R7 or R8; the disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO:10);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9);Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12);Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15);Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18);Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20);Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21);Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24);Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28);Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 29);Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 30);dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35);Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 43);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64);Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68);Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 69);Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:76);Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 119);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2 (SEQID NO: 124);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2 (SEQ ID NO:125);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 130);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQID NO: 132);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 135);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 143);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ IDNO: 144);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 150);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 153);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO:154);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 155);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 161);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 162);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2 (SEQ ID NO: 169);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 170);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2(SEQ ID NO: 174);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 175);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 176);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2 (SEQ IDNO: 177);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO:178);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:179);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:180);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 181);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQID NO: 182);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183);Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184);Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185);Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Tr-Lys-Pro-DNL(2') NO: 186);Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTr-SE-DN-dNal(2') NO: 196);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 203);Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dNal-dNal(2') ID: NO 204);Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205);Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-d SEQ-dNal(2') IDH: 206);Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 240);Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-d Pro-DNVal(2')-IDNO NO:241);Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242);Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys-dNal(2')-Arg-Trp-Lys-d-Pro-IDH2: 244);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245);Ac-Nle-c[Asp-His-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cis-Pro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 261); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 273);Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:274);Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:275);Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:327);Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:328);Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:329);Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330);Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331);Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332);Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 333);Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334);Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335);Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336);Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2 (SEQ ID NO: 349);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2 (SEQ ID NO: 350);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103);Ac-Nle-c[Asp-Ioc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 46);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ IDNO: 56);Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62);Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83);Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338);Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 339);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ IDNO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:225);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514);Ac-Nle-c[Asp-dGln-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 269); Ac-dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 270); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH2 (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 283).;

[0162] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence according to formula (IA): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4 (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His. dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTy R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is the group selected from the following: dPhe, p-Chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, β2-Val, β3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is... The following groups are absent or selected: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the following groups: dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analogue is partially cyclized by the following groups: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, R6 is Trp, and the non-natural melanocortin analogue is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analogue is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, the non-natural melanocortin analogue is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7;When R4 is dPhe, then (i) R3 is not His, Pro, or does not exist; (ii) R3 is His and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg; (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 do not exist simultaneously, or (iv) R3 does not exist and R2 and R7 are not both dPen; and when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized via a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 or Y3 exists.

[0163] In some embodiments, the non-naturally occurring melanocortin analogue comprises a sequence according to formula (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla). Arg, dArg, Lys, dLys, His, dHis, Ornithine (Orn), D-Ornithine (dOrn), D-Leucine (dLeu), D-Tyrosine (dTyr), Phenylalanine (Phe), D-Phenylalanine (dPhe), Tryptophan (Trp), D-Tryptophan (dTrp), Aspartic acid (Asp), Cysteine ​​(Cys), and D-Cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, H is, dHis, Tyr, and dTyr; R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the following: Groups: dPhe, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp Y1 consists of asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 consists of the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dThr, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 consists of the following groups: Val, dVal, Pro, and dPr. o, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; and the non-natural melanocortin analogue is partially cyclized by selecting from the group consisting of: the disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; the disulfide bond between R2 and R7 or R8 when R2 is Cys, R7 is Pen, and R3 is absent. The disulfide bond between R1 or R2; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:380);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);and Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514).;

[0164] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB): X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7(IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys). R1 is histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cis-Pro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-Asparagine (dAsn) and D-Threonine (dThr); Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys and dLys;Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, the non-naturally occurring melanocortin analogue is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1, X2, and X3 are present, then Y3-Y7 are absent.

[0165] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB), wherein: X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D -Phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'- Naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, L Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys.Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analogue does not contain the following sequence: Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639). ;

[0166] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (IC): X1-X2-R1-R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), where: X1 is selected from the following groups: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the following groups: aspartic acid (Asp), cysteine ​​(Cys) and D-cysteine ​​(dCys); R2 is selected from the following groups: tryptophan (Trp), phenylalanine (Phe), D-phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr) and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the following groups: Trp, 2'-D-naphthylalanine (dNal(2')), 2 '-Naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys and dCys; Y1 is absent or selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg and dLys; Y2 is absent or selected from the group consisting of dVal, dPro and D-hydroxyproline (dHyp); Y3 is absent, dVal or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R1 and R7 when both R1 and R7 are independently selected from the group consisting of Cys, dCys and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys; In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (ID): X1-R1-R2-R3-p(Cl)dPhe-Arg-Trp-R7-Y1-Y2-Y3-Y4 (ID), where: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His) and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata) and 4-amino-1,4,5,6-tetrahydroazaza-[4, [3-b] Indole-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and this non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1Y2 is dVal-dPro, X1 is absent, and the non-natural melanocortin analogue is cyclized by disulfide bonds, or (b) Y1Y2 is not dVal-dPro and either X1 or Y3 is present.

[0167] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (ID), wherein: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid. (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), and 4-amino-1,4,5,6-tetrahydrozazaza[4,3-b]indole-3 ( 2H)-keto (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of: D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of: dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-natural melanocortin analogue does not contain a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); and.

[0168] In some implementations, the N-terminus of a non-natural melanocortin analog is modified with an acyl group.

[0169] In some implementations, the acyl group is an acetyl group.

[0170] In some implementations, the N-terminus of non-naturally occurring melanocortin analogues is not modified.

[0171] In some implementations, the C-terminus of a non-natural melanocortin analog is modified with an amide group.

[0172] In some implementations, the C-terminus of the non-natural melanocortin analogue is not modified.

[0173] In some implementations, Y1-Y2 exist, while Y3-Y8 do not.

[0174] In some implementations, Y1 is D-valine and Y2 is D-proline.

[0175] In some embodiments, the technology includes a method or use in which Y1 is D-tert-leucine and Y2 is D-proline.

[0176] In some implementations, R4 is dNal(2').

[0177] In some embodiments, the sequence of formula (I) is: Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), where c represents cyclization via lactam bonds through R2 and R8.

[0178] In some implementations, R4 is Phe or dPhe.

[0179] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296), where c represents cyclization via a lactam bond through R2 and R7.

[0180] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300). 301); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); NO: 310); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311);Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), where c represents cyclization via lactam bonds through R2 and R7.

[0181] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac-Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 319). 321); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 324), where c represents cyclization via disulfide bonds through R2 and R7.

[0182] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 353), where c represents cyclization via lactam bonds through R2 and R8.

[0183] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle-c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355). 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-Ioc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle-c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 373);Ac-Nle-c[Asp-Tyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 214), where c represents cyclization via lactam bonds through R2 and R7.

[0184] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), where c represents cyclization via lactam bonds through R1 and R7.

[0185] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 384). 385); Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp-Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 394);Ac-Nle-c[Asp-Trp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:395);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1']-Lys]-dVal-dPro-NH2 (SEQ ID NO:399);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:403);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:404);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO:405);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO:406);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411);Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 412);Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413);Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), where c represents cyclization via a lactam bond or disulfide bond through R1 and R7.

[0186] In some embodiments, the sequence of any of formulas (I)-(ID) is: Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), where c represents cyclization via lactam bonds through R2 and R8.

[0187] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 421); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 423). 424), where c represents cyclization via lactam bonds through R1 and R7.

[0188] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233). 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 429), where c represents cyclization via lactam bonds through R2 and R7.

[0189] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 434); 435); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 446);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQID NO: 447);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 448);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:449);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:450);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 451);Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:452);Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 453);Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454);Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455);Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456);Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457);Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458);Ac-Nle-c[Cys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 461); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), where c represents cyclization via a lactam bond or a disulfide bond through R2 and R7.

[0190] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211). 499); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 523), where c represents cyclization via a lactam bond or disulfide bond through R2 and R7.

[0191] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), where c represents cyclization via disulfide bonds through R2 and R7.

[0192] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 5775 ... 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 581); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 587);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ IDNO: 594);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:595);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 599);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ 602);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 603);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID 604);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dQNOH2 (Asp-NHal 606);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 607);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 ( 608);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH: NOH2 ( 610);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn:IDPro-NH 612);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID 614);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ IDNO: 620); Ac-Nle-c[dAsp-Pro-dPhe-Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β2Val-βPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β3Val-βPro-NH2 (SEQ ID NO: 626); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-βPro-NH2 (SEQ ID NO: 627), where c represents cyclization via lactam bonds through R2 and R7.

[0193] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), where c represents cyclization via lactam bond through R2 and R7.

[0194] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 633). 634); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645);And Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), where c represents cyclization via lactam bonds through R2 and R7.

[0195] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0196] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 212, 218, 226, 291, 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-598, 600-646.

[0197] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 218, 231-235, 291, 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0198] In some implementations, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 226, 383-393, 399, 403-417.

[0199] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 209-211, 499, 501-506, 511-513, 515, 518-523.

[0200] In some implementations, a non-natural melanocortin analogue is present in the pharmaceutical composition.

[0201] In some embodiments, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and / or carriers.

[0202] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0203] In some embodiments, the non-natural melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 5 mg / kg to about 20 mg / kg for about 5 to about 10 days; (ii) once daily at a second dose of about 10 mg / kg to about 40 mg / kg after the first dose for about 5 to about 10 days; and (iii) twice daily at a third dose of about 5 mg / kg to about 30 mg / kg after the second dose for at least about 5 to about 10 days.

[0204] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 5 mg / kg once a day for about 7 days; (ii) a second dose of about 15 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 10 mg / kg twice a day for at least about 7 days after the second dose.

[0205] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 10 mg / kg once a day for about 7 days; (ii) a second dose of about 20 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 15 mg / kg twice a day for at least about 7 days after the second dose.

[0206] In some embodiments, the technology includes a method or use in which the non-naturally occurring melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 15 mg / kg for about 7 days; (ii) once daily at a second dose of about 25 mg / kg after the first dose for about 7 days; and (iii) twice daily at a third dose of about 20 mg / kg after the second dose for at least about 7 days.

[0207] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 0.5 mg / kg to about 10 mg / kg based on the subject's body weight.

[0208] In some implementations, non-natural melanocorticoid analogues are administered once daily at a dose of about 1 mg / kg or 3 mg / kg based on the subject's body weight.

[0209] In some implementations, non-natural melanocorticoid analogues are administered once daily at doses of about 0.1 mg to about 100 mg.

[0210] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 10 mg or about 50 mg.

[0211] In some implementations, non-natural melanocorticoid analogues are administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

[0212] In some implementations, non-natural melanocortin analogs cross the blood-brain barrier in the subject.

[0213] In some implementations, the non-naturally occurring melanocortin analogue contains SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646, any one of the sequences, and at a dose of 0.001 mg / kg to 25 mg / kg based on the subject's body weight. Administer at least once daily at doses within the mg / kg range.

[0214] In some implementations, non-naturally occurring melanocortin analogues include SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429. The drug is administered at least once daily in any of the sequences 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, and 622-646, at a dose ranging from 0.5 mg / kg to 10 mg / kg based on the subject's body weight.

[0215] In some implementations, non-natural melanocorticoid analogs are administered to subjects for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0216] In some implementations, the non-naturally occurring melanocortin analogue is administered to the subject for 1, 5, 7, 14, 21, 28, 35, 40, 45, 50, 60, 75, 90, 100, 110, or 120 days. In some implementations, the technique includes a method for reducing pain levels in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analogue of formula (I): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (I), where: X1 is absent or selected from the following groups: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3 is absent or selected from the group consisting of: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydrozazaza-[4,3-b]indole-3(2H)-one (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4- Phenyloncyclohexane-carboxylic acid (APC), 4-aminophenylpiperidin-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: A rg, His, cisPro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (β2-Val), and β3-valine (β3-Val). Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 is independently selected from Cys, dCys, and dP. The disulfide bond between R1 or R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, and R6 is Trp. The non-natural melanocortin analogue is not cyclized between Cys at R2 and Cys at R7, or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analogue is cyclized via a disulfide bond between R2 and R7. When R4 is p(Br)dPhe, the non-natural melanocortin analogue is cyclized via a disulfide bond between dCys at R2 and Cys or dCys at R7. When R4 is dPhe, then (i) R3 is not His, Pro, or does not exist; (ii) R3 is His, and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg; (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 are not present simultaneously, or (iv) R3 is absent and R2 and R7 are not both dPen; when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia, and Ata, or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized by a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 exists or Y3 exists; and when R2 is dAla, then R4 is dPhe and Y1-Y7 are absent.

[0217] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing pain levels in a subject in need relative to a control, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0218] In some implementations, the technology includes a method for treating, preventing, or reducing addiction in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0219] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the treatment, prevention, or reduction of addiction in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0220] In some implementations, the technology includes a method for preventing or reducing a subject’s use of or dependence on an addictive substance relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0221] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of a subject’s use or dependence on an addictive substance relative to a control treatment, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0222] In some implementations, the technology includes a method for treating or preventing opioid use disorder (OUD) in a subject in need of control therapy or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0223] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of OUD in a subject in need of control therapy or prevention, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0224] In some implementations, the technology includes a method for treating or preventing alcohol use disorder (AUD) in a subject in need of control treatment or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0225] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of AUD in a subject in need of a control or preventative treatment, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0226] In some implementations, the method or use includes reducing the dosage of the addictive substance used or consumed relative to a control.

[0227] In some implementations, the method or use includes reducing dependence on addictive substances relative to a control.

[0228] In some implementations, the method or use includes reducing the frequency of use of addictive substances relative to a control.

[0229] In some implementations, the method or use includes reducing the dose or amount of a conventional drug used to treat addiction relative to a control.

[0230] In some implementations, the technology includes a method for enhancing the effect of a conventional drug used to treat addiction in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0231] In some embodiments, the technology includes the use of a non-naturally occurring melanocorticoid analogue to enhance the effects of a conventional drug used to treat addiction in a subject in need, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0232] In some implementations, the technology includes a method for reducing or eliminating, relative to a control, the need of a subject for conventional drugs used to treat addiction, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0233] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing or eliminating the need of a subject in need of a conventional drug for treating addiction, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0234] In some implementations, treatment of addiction is improved during or after the administration of this non-natural melanocorticoid analogue compared to treatment of addiction using conventional drugs alone for treating addiction.

[0235] In some implementations, conventional drugs for treating addiction are selected from the group consisting of: buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-α-acetylmethadone (LAAM), codeine, lofexidine, and sustained-release morphine.

[0236] In some implementations, the technology includes a method for reducing hospitalization or rehabilitation needs associated with addiction or use of addictive substances relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0237] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0238] In some implementations, the technology includes a method for preventing or mitigating withdrawal symptoms of an addictive substance in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0239] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of withdrawal symptoms of an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0240] In some implementations, the technology includes a method for preventing or alleviating symptoms associated with withdrawal of an addictive substance in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0241] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of symptoms associated with withdrawal from addictive substances in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0242] In some implementation schemes, symptoms associated with withdrawal from addictive substances are selected from the following groups: pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle pain, nausea, sleep problems, suicidal ideation, tremor, and visual impairment.

[0243] In some implementation schemes, the subjects are addicted to or prone to addiction to addictive substances.

[0244] In some implementations, the subject has used or is currently using one or more addictive substances.

[0245] In some implementations, this technology includes a method or use in which addictive substances include prescription drugs, substances in over-the-counter drugs, recreational substances, or illicit substances.

[0246] In some implementations, the addictive substance is selected from the group consisting of: opioids, analgesics, stimulants, narcotics, alcohol, sedatives, marijuana, cannabis products, tetrahydrocannabinol (THC), cannabidiol (CBD), and inhalants.

[0247] In some implementations, the opioid substance is selected from the group consisting of: morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0248] In some implementations, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamine, cocaine, and amphetamine.

[0249] In some implementations, the sedative includes barbiturates or benzodiazepines.

[0250] In some implementations, the barbiturates are selected from the group consisting of: phenobarbital, mesobarbital, buprofen, pentobarbital, primidone, and amobarbital.

[0251] In some implementation schemes, benzodiazepines are selected from the group consisting of: alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0252] In some implementations, the sedative is selected from the group consisting of: diazepam, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0253] In some implementations, the inhalant is selected from the group consisting of: aerosols, butane, Freon, helium, nitrous oxide, propane, and nitrite.

[0254] In some implementations, nicotine includes tobacco chewing products, nicotine pouches, or smoking devices.

[0255] In some implementations, the smoking device is selected from the group consisting of: cigarettes, electronic cigarettes, cigars, and electronic cigarette products.

[0256] In some implementations, the control group includes the subject prior to administration of the non-naturally occurring melanocorticoid analogue.

[0257] In some implementations, the control group includes the subject at baseline.

[0258] In some implementations, the non-natural melanocortin analogue is a melanocortin 4 receptor (MC4R) agonist.

[0259] In some implementations, the MC4R agonist is a full-type MC4R agonist.

[0260] In some implementations, the MC4R agonist is a partial MC4R agonist.

[0261] In some implementations, non-natural melanocortin analogs are MC3R antagonists.

[0262] In some implementations, the MC3R antagonist is a full-type MC3R antagonist.

[0263] In some implementations, the MC3R agonist is a partial MC3R agonist.

[0264] In some implementations, non-natural melanocortin analogs do not have MC3R activity.

[0265] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence according to formula (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. The following are the groups selected for R2: Acid (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is either absent or selected from the group consisting of: His, Ala, Pr o, Hydroxyproline (Hyp), Leucine (Leu), D-Glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-Amino-1,2,4,5-Tetrahydro-2-benzozaza-3-one (Aba), 7-Amino-7,8-Dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-Amino-1,4,5,6-Tetrahydrozazaza-[4,3-b]indol-3(2H)-one (Aia), 2-Aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-Amino-4-phenylcyclohexane-carboxylic acid (APC), 4-Aminophenylpiperidine-4-carboxylic acid (AP) PC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan);R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg. Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen. The disulfide bond between R1 or R2 and R7 or R8; the disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO:10);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9);Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12);Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15);Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18);Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20);Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21);Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24);Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28);Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 29);Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 30);dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35);Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 43);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64);Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68);Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 69);Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:76);Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 119);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2 (SEQID NO: 124);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2 (SEQ ID NO:125);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 130);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQID NO: 132);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 135);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 143);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ IDNO: 144);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 150);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 153);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO:154);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 155);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 161);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 162);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2 (SEQ ID NO: 169);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 170);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2(SEQ ID NO: 174);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 175);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 176);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2 (SEQ IDNO: 177);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO:178);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:179);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:180);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 181);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQID NO: 182);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183);Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184);Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185);Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Tr-Lys-Pro-DNL(2') NO: 186);Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTr-SE-DN-dNal(2') NO: 196);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 203);Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dNal-dNal(2') ID: NO 204);Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205);Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-d SEQ-dNal(2') IDH: 206);Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 240);Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-d Pro-DNVal(2')-IDNO NO:241);Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242);Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys-dNal(2')-Arg-Trp-Lys-d-Pro-IDH2: 244);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245);Ac-Nle-c[Asp-His-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cis-Pro(guan)Pro-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 251); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 253); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH₂ (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 261); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 273);Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:274);Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:275);Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:327);Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:328);Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:329);Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330);Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331);Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332);Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 333);Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334);Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335);Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336);Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2 (SEQ ID NO: 349);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2 (SEQ ID NO: 350);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103);Ac-Nle-c[Asp-Ioc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 46);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ IDNO: 56);Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62);Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83);Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338);Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 339);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ IDNO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621); Ac-Nle-c[Asp-His-dPhe-transPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cisPro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:225);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2(SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514);Ac-Nle-c[Asp-dGln-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH₂ (SEQ ID NO: 269); Ac-dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 270); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH₂ (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-NH₂ (SEQ ID NO: 283).;

[0266] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence according to formula (IA): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4 (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His. dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTy R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is the group selected from the following: dPhe, p-Chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, β2-Val, β3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is... The following groups are absent or selected: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the following groups: dVal, dPro, Asp, and dAsp; and the non-naturally occurring melanocortin analogue is partially cyclized by the following groups: a disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; a disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen, and R3 is absent; a lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and a lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, R6 is Trp, and the non-natural melanocortin analogue is not cyclized between Cys at R2 and Cys at R7 or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analogue is cyclized through a disulfide bond between R2 and R7, where R2 and R7 are the same; when R4 is p(Br)dPhe, the non-natural melanocortin analogue is cyclized through a disulfide bond between dCys at R2 and Cys or dCys at R7;When R4 is dPhe, then (i) R3 is not His, Pro, or does not exist; (ii) R3 is His and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg; (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 do not exist simultaneously, or (iv) R3 does not exist and R2 and R7 are not both dPen; and when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia, and Ata or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized via a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 or Y3 exists.

[0267] In some embodiments, the non-naturally occurring melanocortin analogue comprises a sequence according to formula (IA), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla). Arg, dArg, Lys, dLys, His, dHis, Ornithine (Orn), D-Ornithine (dOrn), D-Leucine (dLeu), D-Tyrosine (dTyr), Phenylalanine (Phe), D-Phenylalanine (dPhe), Tryptophan (Trp), D-Tryptophan (dTrp), Aspartic acid (Asp), Cysteine ​​(Cys), and D-Cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, H is, dHis, Tyr, and dTyr; R3 is the group that is absent or selected from the following: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the following: Groups: dPhe, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is Arg or His; R6 is selected from the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys;Y1 is selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp Y1 consists of asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 consists of the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dThr, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 consists of the following groups: Val, dVal, Pro, and dPr. o, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; and the non-natural melanocortin analogue is partially cyclized by selecting from the group consisting of: the disulfide bond between R1 or R2 and R7 or R8 when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen; the disulfide bond between R2 and R7 or R8 when R2 is Cys, R7 is Pen, and R3 is absent. The disulfide bond between R1 or R2; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 549);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 551);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:552);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:553);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555);Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563);Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564);Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565);Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568);Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569);Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570);Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571);Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544);Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561);Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 542);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 560);Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:543);Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550);Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558);Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418);Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621);Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639);Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326);Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401);Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225);Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2(SEQ ID NO: 430);Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ IDNO: 431);Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:380);Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215);Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525);Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526);Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527);Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531);Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533);Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534);Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532);Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498);Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 509);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 510);Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508);Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 507);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517);Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 500);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516);and Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 514).;

[0268] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB): X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7(IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys). R1 is histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cis-Pro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-Asparagine (dAsn) and D-Threonine (dThr); Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys and dLys;Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that: when R4 is p(F)dPhe, the non-naturally occurring melanocortin analogue is not cyclized between Cys at R2 and Cys at R7; and when R4 is dPhe and one or more of X1, X2, and X3 are present, then Y3-Y7 are absent.

[0269] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IB), wherein: X1-X2-X3-R1-R2-Pro-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (IB), wherein: X1 is absent or leucine (Nle); X2 is absent or Nle; X3 is absent or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D -Phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R2 is selected from the group consisting of: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R4 is dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan); R6 is selected from the group consisting of: Trp, dTrp, Phe, Aia, Aba, Ata, and 1'- Naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (b2-Val), β3-valine (b3-Val), Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, L Y2 is the group that is absent or selected from the following: Val, dVal, b2-Val, b3-Val, Pro, dPro, b-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn; Y3 is the group that is absent or selected from the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys.Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by: a disulfide bond between R2 and R7 when each of R2 and R7 is independently selected from the group consisting of Cys, dCys, and dPen; and a lactam bridge between R2 and R7 when R2 is Asp or dAsp and R7 is Lys, dLys, or Orn; provided that the non-naturally occurring melanocortin analogue does not contain the following sequence: Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639). ;

[0270] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (IC): X1-X2-R1-R2-Pro-dPhe-R5-R6-R7-Y1-Y2-Y3-Y4 (IC), where: X1 is selected from the following groups: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis); X2 is absent or Nle; R1 is selected from the following groups: aspartic acid (Asp), cysteine ​​(Cys) and D-cysteine ​​(dCys); R2 is selected from the following groups: tryptophan (Trp), phenylalanine (Phe), D-phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr) and D-tyrosine (dTyr); R5 is Arg; R6 is selected from the following groups: Trp, 2'-D-naphthylalanine (dNal(2')), 2 '-Naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the group consisting of Lys, Cys and dCys; Y1 is absent or selected from the group consisting of D-valine (dVal), D-tert-leucine (dTle), dArg and dLys; Y2 is absent or selected from the group consisting of dVal, dPro and D-hydroxyproline (dHyp); Y3 is absent, dVal or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R1 and R7 when both R1 and R7 are independently selected from the group consisting of Cys, dCys and dPen; and a lactam bridge between R1 and R7 when R1 is Asp and R7 is Lys; In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analog comprises the sequence of formula (ID): X1-R1-R2-R3-p(Cl)dPhe-Arg-Trp-R7-Y1-Y2-Y3-Y4 (ID), where: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His) and D-histidine (dHis); R2 is aspartic acid (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata) and 4-amino-1,4,5,6-tetrahydroazaza-[4, [3-b] Indole-3(2H)-one (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and this non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that when R3 is His and R1 is Nle, then (i) Y1Y2 is dVal-dPro, X1 is absent, and the non-natural melanocortin analogue is cyclized by disulfide bonds, or (b) Y1Y2 is not dVal-dPro and either X1 or Y3 is present.

[0271] In some embodiments, the technology includes a method or use wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (ID), wherein: X1 is absent or leucine (Nle); R1 is selected from the group consisting of: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R2 is aspartic acid. (Asp) or D-cysteine ​​(dCys); R3 is selected from the group consisting of: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), and 4-amino-1,4,5,6-tetrahydrozazaza[4,3-b]indole-3 ( 2H)-keto (Aia); R7 is Lys or dCys; Y1 is selected from the group consisting of: D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y2 is absent or selected from the group consisting of: dVal, dPro, and dTle; Y3 is absent, dVal, or dPro; Y4 is absent or dPro; and the non-natural melanocortin analogue is partially cyclized by the group consisting of: a disulfide bond between R2 and R7 when both R2 and R7 are dCys; and a lactam bridge between R2 and R7 when R2 is Asp and R7 is Lys; provided that the non-natural melanocortin analogue does not contain a sequence selected from the group consisting of: Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); and.

[0272] In some implementations, the N-terminus of a non-naturally occurring melanocortin analog is modified with an acyl group.

[0273] In some implementations, the acyl group is an acetyl group.

[0274] In some implementations, the N-terminus of non-naturally occurring melanocortin analogues is not modified.

[0275] In some implementations, the C-terminus of a non-natural melanocortin analog is modified with an amide group.

[0276] In some implementations, the C-terminus of the non-natural melanocortin analogue is not modified.

[0277] In some implementations, Y1-Y2 exist, while Y3-Y8 do not.

[0278] In some implementations, Y1 is D-valine and Y2 is D-proline.

[0279] In some embodiments, the technology includes a method or use in which Y1 is D-tert-leucine and Y2 is D-proline.

[0280] In some implementations, R4 is dNal(2').

[0281] In some embodiments, the sequence of formula (I) is: Ac-Nle-c[Asp-His-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), where c represents cyclization via lactam bonds through R2 and R8.

[0282] In some implementations, R4 is Phe or dPhe.

[0283] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296), where c represents cyclization via a lactam bond through R2 and R7.

[0284] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300). 301); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); NO: 310); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311);Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), where c represents cyclization via lactam bonds through R2 and R7.

[0285] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac-Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 319). 321); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 324), where c represents cyclization via disulfide bonds through R2 and R7.

[0286] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO: 353), where c represents cyclization via lactam bonds through R2 and R8.

[0287] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle-c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355). 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-Ioc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle-c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 373);Ac-Nle-c[Asp-Tyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 214), where c represents cyclization via lactam bonds through R2 and R7.

[0288] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), where c represents cyclization via lactam bonds through R1 and R7.

[0289] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 384). 385); Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp-Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 394);Ac-Nle-c[Asp-Trp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:395);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1']-Lys]-dVal-dPro-NH2 (SEQ ID NO:399);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:403);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:404);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO:405);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO:406);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410);Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411);Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 412);Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413);Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), where c represents cyclization via a lactam bond or disulfide bond through R1 and R7.

[0290] In some embodiments, the sequence of any of formulas (I)-(ID) is: Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), where c represents cyclization via lactam bonds through R2 and R8.

[0291] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 421); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 423). 424), where c represents cyclization via lactam bonds through R1 and R7.

[0292] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233). 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 429), where c represents cyclization via lactam bonds through R2 and R7.

[0293] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 434); 435); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ IDNO: 446);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQID NO: 447);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 448);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:449);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:450);Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ IDNO: 451);Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:452);Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 453);Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454);Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455);Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456);Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457);Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458);Ac-Nle-c[Cys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459);Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 461); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), where c represents cyclization via a lactam bond or a disulfide bond through R2 and R7.

[0294] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 211). 499); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 512); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 513);Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 515); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 523), where c represents cyclization via a lactam bond or disulfide bond through R2 and R7.

[0295] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), where c represents cyclization via disulfide bonds through R2 and R7.

[0296] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 5775 ... 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 581); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 587);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ IDNO: 594);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:595);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 597);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO: 598);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 599);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ 602);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 603);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID 604);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dQNOH2 (Asp-NHal 606);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 607);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 ( 608);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH: NOH2 ( 610);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn:IDPro-NH 612);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID 614);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615);Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ IDNO: 620); Ac-Nle-c[dAsp-Pro-dPhe-Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β2Val-NH2 (SEQ ID NO: 623); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β3Val-NH2 (SEQ ID NO: 624); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β2Val-βPro-NH2 (SEQ ID NO: 625); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β3Val-βPro-NH2 (SEQ ID NO: 626); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-βPro-NH2 (SEQ ID NO: 627), where c represents cyclization via lactam bonds through R2 and R7.

[0297] In some embodiments, the sequence of any of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 630), where c represents cyclization via lactam bond through R2 and R7.

[0298] In some implementations, the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 633). 634); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645);And Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), where c represents cyclization via lactam bonds through R2 and R7.

[0299] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

[0300] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 212, 218, 226, 291, 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-598, 600-646.

[0301] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 187, 218, 231-235, 291, 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

[0302] In some implementations, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 226, 383-393, 399, 403-417.

[0303] In some embodiments, the non-naturally occurring melanocortin analogue comprises any one of the sequences of SEQ ID NO: 209-211, 499, 501-506, 511-513, 515, 518-523.

[0304] In some implementations, a non-natural melanocortin analogue is present in the pharmaceutical composition.

[0305] In some embodiments, the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and / or carriers.

[0306] In some embodiments, the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition include water.

[0307] In some embodiments, the non-natural melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 5 mg / kg to about 20 mg / kg for about 5 to about 10 days; (ii) once daily at a second dose of about 10 mg / kg to about 40 mg / kg after the first dose for about 5 to about 10 days; and (iii) twice daily at a third dose of about 5 mg / kg to about 30 mg / kg after the second dose for at least about 5 to about 10 days.

[0308] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 5 mg / kg once a day for about 7 days; (ii) a second dose of about 15 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 10 mg / kg twice a day for at least about 7 days after the second dose.

[0309] In some implementations, the non-natural melanocorticoid analogue is administered as follows: (i) a first dose of about 10 mg / kg once a day for about 7 days; (ii) a second dose of about 20 mg / kg once a day for about 7 days after the first dose; and (iii) a third dose of about 15 mg / kg twice a day for at least about 7 days after the second dose.

[0310] In some embodiments, the technology includes a method or use in which the non-naturally occurring melanocorticoid analogue is administered as follows: (i) once daily at a first dose of about 15 mg / kg for about 7 days; (ii) once daily at a second dose of about 25 mg / kg after the first dose for about 7 days; and (iii) twice daily at a third dose of about 20 mg / kg after the second dose for at least about 7 days.

[0311] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 0.5 mg / kg to about 10 mg / kg based on the subject's body weight.

[0312] In some implementations, non-natural melanocorticoid analogues are administered once daily at a dose of about 1 mg / kg or 3 mg / kg based on the subject's body weight.

[0313] In some implementations, non-natural melanocorticoid analogues are administered once daily at doses of about 0.1 mg to about 100 mg.

[0314] In some implementations, a non-natural melanocorticoid analogue is administered once daily at a dose of about 10 mg or about 50 mg.

[0315] In some implementations, non-natural melanocorticoid analogues are administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

[0316] In some implementations, non-natural melanocortin analogs cross the blood-brain barrier in the subject.

[0317] In some implementations, the non-naturally occurring melanocortin analogue contains SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646, any one of the sequences, and at a dose of 0.001 mg / kg to 25 mg / kg based on the subject's body weight. Administer at least once daily at doses within the mg / kg range.

[0318] In some implementations, non-naturally occurring melanocortin analogues include SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429. The drug is administered at least once daily in any of the sequences 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, and 622-646, at a dose ranging from 0.5 mg / kg to 10 mg / kg based on the subject's body weight.

[0319] In some implementations, non-natural melanocorticoid analogs are administered to subjects for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

[0320] In some implementations, the non-naturally occurring melanocortin analogue is administered to the subject for 1, 5, 7, 14, 21, 28, 35, 40, 45, 50, 60, 75, 90, 100, 110, or 120 days. In some implementations, the technique includes a method for reducing pain levels in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analogue of formula (I): X1-X2-X3-R1-R2-R3-R4-R5-R6-R7-R8-Y1-Y2-Y3-Y4-Y5-Y6-Y7 (I), where: X1 is absent or selected from the following groups: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr;R3 is absent or selected from the group consisting of: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydrozazaza-[4,3-b]indole-3(2H)-one (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4- Phenyloncyclohexane-carboxylic acid (APC), 4-aminophenylpiperidin-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: A rg, His, cisPro(guan), and transPro(guan); R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')), and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), β2-valine (β2-Val), and β3-valine (β3-Val). Pro, D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp, and dAsn;Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 is independently selected from Cys, dCys, and dP. The disulfide bond between R1 or R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that: when R4 is dNal(2'), then R3 is His and R7 is Pro; when R4 is p(F)dPhe, then (i) R3 is selected from Pro, dGln, dTyr, and R6 is Trp. The non-natural melanocortin analogue is not cyclized between Cys at R2 and Cys at R7, or (ii) R3 is His and either R6 is Nal(2'), or the non-natural melanocortin analogue is cyclized via a disulfide bond between R2 and R7. When R4 is p(Br)dPhe, the non-natural melanocortin analogue is cyclized via a disulfide bond between dCys at R2 and Cys or dCys at R7. When R4 is dPhe, then (i) R3 is not His, Pro, or does not exist; (ii) R3 is His, and either R2 is Phe or dAla, or R2 is Ala and X1 is Arg or dArg; (iii) R3 is Pro and (a) R2 is Trp, and R5 is not His or R6 is not Phe or (b) R2 is not Trp or Pro, and either R5 is not dNal(2') or Nal(2'), or X1 and Y3 are not present simultaneously, or (iv) R3 is absent and R2 and R7 are not both dPen; when R4 is p(Cl)dPhe, then (i) R3 is selected from Aba, Aia, and Ata, or (ii) R3 is His, R1 is not Ala, and (a) if R1 is Nle and Y1Y2 is dVal-dPro, then X1 is absent and the non-naturally occurring melanocortin analog is cyclized by a disulfide bond between dCys at R2 and dCsys at R7, or (b) if R1 is Nle and Y1Y2 is not dVal-dPro, then either X1 exists or Y3 exists; and when R2 is dAla, then R4 is dPhe and Y1-Y7 are absent.

[0321] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing pain levels in a subject in need relative to a control, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0322] In some implementations, the technology includes a method for treating, preventing, or reducing addiction in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0323] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the treatment, prevention, or reduction of addiction in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0324] In some implementations, the technology includes a method for preventing or reducing a subject’s use of or dependence on an addictive substance relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0325] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of a subject’s use or dependence on an addictive substance relative to a control treatment, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0326] In some implementations, the technology includes a method for treating or preventing opioid use disorder (OUD) in a subject in need of control therapy or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0327] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of OUD in a subject in need of control therapy or prevention, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0328] In some implementations, the technology includes a method for treating or preventing alcohol use disorder (AUD) in a subject in need of control treatment or prevention, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0329] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for the treatment or prevention of AUD in a subject in need of a control or preventative treatment, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0330] In some implementations, the method or use includes reducing the dosage of the addictive substance used or consumed relative to a control.

[0331] In some implementations, the method or use includes reducing dependence on addictive substances relative to a control.

[0332] In some implementations, the method or use includes reducing the frequency of use of addictive substances relative to a control.

[0333] In some implementations, the method or use includes reducing the dose or amount of a conventional drug used to treat addiction relative to a control.

[0334] In some implementations, the technology includes a method for enhancing the effect of a conventional drug used to treat addiction in a subject in need relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0335] In some embodiments, the technology includes the use of a non-naturally occurring melanocorticoid analogue to enhance the effects of a conventional drug used to treat addiction in a subject in need, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0336] In some implementations, the technology includes a method for reducing or eliminating, relative to a control, the need of a subject for conventional drugs used to treat addiction, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0337] In some implementations, the technology includes the use of a non-naturally occurring melanocorticoid analogue for reducing or eliminating the need of a subject in need of a conventional drug for treating addiction, the non-naturally occurring melanocorticoid analogue comprising the sequence of formula (I).

[0338] In some implementations, treatment of addiction is improved during or after the administration of this non-natural melanocorticoid analogue compared to treatment of addiction using conventional drugs alone for treating addiction.

[0339] In some implementations, conventional drugs for treating addiction are selected from the group consisting of: buprenorphine, naltrexone, acamprosate, methadone, naloxone, nalmefene, xycodone, levo-α-acetylmethadone (LAAM), codeine, lofexidine, and sustained-release morphine.

[0340] In some implementations, the technology includes a method for reducing hospitalization or rehabilitation needs associated with addiction or use of addictive substances relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0341] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0342] In some implementations, the technology includes a method for preventing or mitigating withdrawal symptoms of an addictive substance in a subject, the method comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

[0343] In some embodiments, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of withdrawal symptoms of an addictive substance in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0344] In some implementations, the technology includes a method for preventing or alleviating symptoms associated with withdrawal of an addictive substance in a subject relative to a control, the method comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

[0345] In some implementations, the technology includes the use of a non-naturally occurring melanocortin analogue for the prevention or reduction of symptoms associated with withdrawal from addictive substances in a subject relative to a control, the non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

[0346] In some implementation schemes, symptoms associated with withdrawal from addictive substances are selected from the following groups: pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle pain, nausea, sleep problems, suicidal ideation, tremor, and visual impairment.

[0347] In some implementation schemes, the subjects are addicted to or prone to addiction to addictive substances.

[0348] In some implementations, the subject has used or is currently using one or more addictive substances.

[0349] In some implementations, this technology includes a method or use in which addictive substances include prescription drugs, substances in over-the-counter drugs, recreational substances, or illicit substances.

[0350] In some implementations, the addictive substance is selected from the group consisting of: opioids, analgesics, stimulants, narcotics, alcohol, sedatives, marijuana, cannabis products, tetrahydrocannabinol (THC), cannabidiol (CBD), and inhalants.

[0351] In some implementations, the opioid substance is selected from the group consisting of: morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

[0352] In some implementations, the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamine, cocaine, and amphetamine.

[0353] In some implementations, the sedative includes barbiturates or benzodiazepines.

[0354] In some implementations, the barbiturates are selected from the group consisting of: phenobarbital, mesobarbital, buprofen, pentobarbital, primidone, and amobarbital.

[0355] In some implementation schemes, benzodiazepines are selected from the group consisting of: alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

[0356] In some implementations, the sedative is selected from the group consisting of: diazepam, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

[0357] In some implementations, the inhalant is selected from the group consisting of: aerosols, butane, Freon, helium, nitrous oxide, propane, and nitrite.

[0358] In some implementations, nicotine includes tobacco chewing products, nicotine pouches, or smoking devices.

[0359] In some implementations, the smoking device is selected from the group consisting of: cigarettes, electronic cigarettes, cigars, and electronic cigarette products.

[0360] In some implementations, the control group includes the subject prior to administration of the non-naturally occurring melanocorticoid analogue.

[0361] In some implementations, the control group includes the subject at baseline.

[0362] In some implementations, the non-natural melanocortin analogue is a melanocortin 4 receptor (MC4R) agonist.

[0363] In some implementations, the MC4R agonist is a full-type MC4R agonist.

[0364] In some implementations, the MC4R agonist is a partial MC4R agonist.

[0365] In some implementations, non-natural melanocortin analogs are MC3R antagonists.

[0366] In some implementations, the MC3R antagonist is a full-type MC3R antagonist.

[0367] In some implementations, the MC3R agonist is a partial MC3R agonist.

[0368] In some implementations, non-natural melanocortin analogs do not have MC3R activity.

[0369] In some embodiments, the non-naturally occurring melanocortin analogue comprises the sequence according to formula (I), wherein: X1 is absent or selected from the group consisting of: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X2 is absent, phenylalanine (Phe), or Nle; X3 is absent, Phe, or Nle; R1 is selected from the group consisting of: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine. The following are the groups selected for R2: Acid (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R2 is selected from the group consisting of: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R3 is either absent or selected from the group consisting of: His, Ala, Pr o, Hydroxyproline (Hyp), Leucine (Leu), D-Glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-Amino-1,2,4,5-Tetrahydro-2-benzozaza-3-one (Aba), 7-Amino-7,8-Dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-Amino-1,4,5,6-Tetrahydrozazaza-[4,3-b]indol-3(2H)-one (Aia), 2-Aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-Amino-4-phenylcyclohexane-carboxylic acid (APC), 4-Aminophenylpiperidine-4-carboxylic acid (AP) PC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indole-2-carboxylic acid (Ioc), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R4 is selected from the group consisting of: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R5 is selected from the group consisting of: Arg, His, cisPro(guan), and transPro(guan);R6 is selected from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R7 is selected from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen and Orn; R8 is absent or Lys; Y1 is absent or selected from the following groups: valine (Val), D-valine (dVal), b2-valine (b2-Val), b3-valine (b3-Val), Pro D-proline (dPro), β-proline (b-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y2 is absent or selected from the following groups: Val, dVal, b2-Val, b3-Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg. Gly, Ala, dAla, Asp, and dAsn; Y3 is absent or selected from the group consisting of: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y4 is absent or selected from the group consisting of: dVal, dPro, Asp, and dAsp; Y5 is absent or dVal; Y6 is absent or dVal; Y7 is absent or dPro; and the non-naturally occurring melanocortin analogue is partially cyclized by selecting from the group consisting of: when each of R1 or R2 and R7 or R8 is independently selected from the group consisting of Cys, dCys, and dPen. The disulfide bond between R1 or R2 and R7 or R8; the disulfide bond between R2 and R7 when R2 is Cys, R7 is Pen and R3 is absent; the lactam bridge between R1 or R2 and R7 or R8 when R1 or R2 is Asp and R7 or R8 is Lys or Orn; and the lactam bridge between R2 and R7 when R2 is dAsp and R7 is dLys; provided that the non-natural melanocortin analog does not include sequences selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5);Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO:10);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6);Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7);Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9);Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 12);Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15);Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18);Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20);Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21);Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24);Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28);Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 29);Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 30);dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35);Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42);Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 43);Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64);Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68);Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQID NO: 69);Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:76);Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 119);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2 (SEQID NO: 124);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2 (SEQ ID NO:125);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 130);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQID NO: 132);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 135);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2(SEQ ID NO: 143);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ IDNO: 144);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO:145);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 150);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2(SEQ ID NO: 153);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO:154);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 155);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO: 159);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 161);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 162);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 164);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO: 167);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2 (SEQ ID NO: 169);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 170);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO: 171);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2(SEQ ID NO: 174);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2(SEQ ID NO: 175);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2(SEQ ID NO: 176);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2 (SEQ IDNO: 177);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO:178);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:179);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:180);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 181);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQID NO: 182);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183);Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184);Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 185);Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Tr-Lys-Pro-DNL(2') NO: 186);Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTr-SE-DN-dNal(2') NO: 196);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 203);Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dNal-dNal(2') ID: NO 204);Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205);Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-d SEQ-dNal(2') IDH: 206);Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 240);Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-d Pro-DNVal(2')-IDNO NO:241);Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242);Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys-dNal(2')-Arg-Trp-Lys-d-Pro-IDH2: 244);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245);Ac-Nle-c[Asp-His-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 247); Ac-Nle-c[Asp-His-dNal(2')-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 248); Ac-Nle-c[Asp-Pro-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 250); Ac-Nle-c[Asp-Pro-dNal(2')-cis-Pro(guan)Pro-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 251); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 253); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH₂ (SEQ ID NO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 261); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH₂ (SEQ ID NO: 263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH₂ (SEQ ID NO: 273);Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:274);Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:275);Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:327);Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:328);Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO:329);Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330);Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331);Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332);Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 333);Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334);Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335);Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336);Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO: 344);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO: 345);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2 (SEQ ID NO: 349);Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2 (SEQ ID NO: 350);Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103);Ac-Nle-c[Asp-Ioc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 46);Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47);Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ IDNO: 56);Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62);Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83);Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338);Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 339);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469);Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 474);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 475);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477);Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 478);Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481);Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482);Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483);Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2(SEQ ID NO: 484);Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQID NO: 485);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:463);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462);Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 473);Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480);Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491);Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489);Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 444);Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445);Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495);Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487);Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488);Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494);Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 471);Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432);Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2(SEQ ID NO: 222);Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQID NO: 535);Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:538);Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545);Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 547);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 548);Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 549);Ac-Nl...

Claims

1. A method for reducing pain levels in a subject in need relative to a control, comprising administering to said subject a non-naturally occurring melanocortin analog of formula (I): X 1 -X 2 -X 3 -R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 -R 8 -Y 1 -Y 2 -Y 3 -Y 4 -Y 5 -Y 6 -Y 7 (I), in: X 1 The group consisting of the following is not present or selected: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X 2 The following are not present: phenylalanine (Phe) or Nle; X 3 For non-existent, Phe, or Nle; R 1 Select from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R 2 Select from the following groups: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R 3 The following groups are not present or are selected: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydrozazaza-[4,3] -b Indole-3 ( 2H )-ketone (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indolin-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip); R 4 Select from the following groups: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe) and p-fluoro-D-phenylalanine (p(F)dPhe); R 5 Choose from the following groups: Arg, His, cis Pro(guan), and trans Pro(guan); R 6 Select the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 The group consisting of the following is not present or is selected: valine (Val), D-valine (dVal), β-valine. 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; Y 5 It is either non-existent or dVal; Y 6 It is either non-existent or dVal; Y 7 If it does not exist or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 1 or R 2 and R 7 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 1 or R 2 With R 7 disulfide bonds between them; When R 2 For Cys, R 7 For Pen and R 3 When R does not exist 2 With R 7 disulfide bonds between them; When R 1 or R 2 For Asp and R 7 Or R 8 When R is Lys or Orn 1 Or R 2 With R 7 Or R 8 The lactam bridge between them; and When R 2 For dAsp and R 7 When R is dLys 2 With R 7 The lactam bridge between them; The premise is: When R 4 When dNal(2'), then R 3 For His and R 7 For Pro; When R 4 When p(F)dPhe, then (i) R 3 Selected from Pro, dGln, dTyr, R 6 For Trp, and the non-naturally occurring melanocortin analogue is not in R. 2 Cys and R at the location 7 Cys are cyclic at the location; or (ii) R 3 For His, and either R 6 For Nal(2'), or the non-naturally occurring melanocortin analogue via R 2 With R 7 Disulfide bond cyclization between them; When R 4 When the value is p(Br)dPhe, the non-natural melanocortin analogue is obtained through R. 2 dCys and R at the location 7 Disulfide bond cyclization between Cys or dCys at the site; When R 4 When dPhe is true, then (i) R 3 (ii) R 3 For His, and either R 2 For Phe or dAla, or R 2 For Ala and X 1 For Arg or dArg, (iii) R 3 For Pro and (a) R 2 For Trp, and R 5 Not His or R 6 Not for Phe or (b) R 2 Not Trp or Pro, and either R 5 It is not dNal(2') or Nal(2'), or X 1 and Y 3 They do not exist simultaneously, or (iv) R 3 For does not exist and R 2 and R 7 Not all are dPen; When R 4 When p(Cl)dPhe is true, then (i) R 3 Selected from Aba, Aia, and Ata or (ii) R 3 For His, R 1 Not Ala, and (a) if R 1 For Nle and Y 1 Y 2 If it is dVal-dPro, then X 1 For non-existent and non-naturally occurring melanocortin analogues, via R 2 dCys and R at the location 7 Disulfide bond cyclization between dCsys at the location, or (b) if R 1 For Nle and Y 1 Y 2 If it is not dVal-dPro, then it is either X 1 Existence, or Y 3 Existence; and When R 2 When it is dAla, then R 4 For dPhe and Y 1 -Y 7 It does not exist.

2. Use of a non-naturally occurring melanocortin analogue for reducing pain levels in a subject in need relative to a control, said non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

3. A method for treating, preventing, or reducing addiction in a subject relative to a control group, comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

4. The use of a non-naturally occurring melanocortin analogue for the treatment, prevention or reduction of addiction in a subject relative to a control, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (I).

5. A method for preventing or reducing a subject's use or dependence on an addictive substance relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

6. The use of a non-naturally occurring melanocortin analogue for the treatment, prevention or reduction of a subject’s use or dependence on an addictive substance relative to a control, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (I).

7. A method for treating or preventing opioid use disorder (OUD) in a subject in need of control therapy or prevention, comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

8. Use of a non-naturally occurring melanocortin analogue for the treatment or prevention of OUD in subjects in need of control therapy or prevention, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (I).

9. A method for treating or preventing alcohol use disorder (AUD) in a subject in need of control treatment, comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

10. Use of a non-naturally occurring melanocorticoid analogue for AUD in subjects requiring treatment or prevention relative to a control, wherein the non-naturally occurring melanocorticoid analogue comprises the sequence of formula (I).

11. The method or use as claimed in any one of claims 3-9, wherein the method or use comprises reducing the dosage of the addictive substance used or consumed relative to a control.

12. The method or use as claimed in any one of claims 3-11, wherein the method or use comprises reducing dependence on addictive substances relative to a control.

13. The method or use as claimed in any one of claims 3-12, wherein the method or use comprises reducing the frequency of use of the addictive substance relative to a control.

14. The method or use as described in any one of claims 3-13, wherein the method or use comprises reducing the dose or amount of a conventional drug used to treat addiction relative to a control.

15. A method for enhancing the effect of a conventional drug used to treat addiction in a subject in need relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

16. Use of a non-naturally occurring melanocortin analogue for enhancing the effect of a conventional medicine used to treat addiction in a subject in need, said non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

17. A method for reducing or eliminating, relative to a control, the need of a subject for a conventional drug used to treat addiction, comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

18. The use of a non-naturally occurring melanocortin analogue for reducing or eliminating the need of a subject in need of a conventional medicine used to treat addiction, said non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

19. The method or use of claim 17 or 18, wherein during or after administration of the non-naturally occurring melanocortin analogue, the treatment of the addiction is improved relative to treatment of the addiction using the conventional drug alone for treating the addiction.

20. The method or use of any one of claims 14-19, wherein the conventional drug for treating the addiction is selected from the group consisting of: buprenorphine, naltrexone, acampolic acid, methadone, naloxone, nalmefone, oxycodone, levo-α-acetylmethadone (LAAM), codeine, lofexidine, and sustained-release morphine.

21. A method for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analogue containing the sequence of formula (I).

22. The use of a non-naturally occurring melanocortin analogue for reducing hospitalization or rehabilitation needs related to addiction or use of addictive substances relative to a control, said non-naturally occurring melanocortin analogue comprising the sequence of formula (I).

23. A method for preventing or mitigating withdrawal symptoms of an addictive substance in a subject, comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

24. Use of a non-naturally occurring melanocortin analogue for the prevention or reduction of withdrawal symptoms of an addictive substance in a subject relative to a control, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (I).

25. A method for preventing or alleviating symptoms associated with withdrawal of an addictive substance in a subject relative to a control, comprising administering to the subject a non-naturally occurring melanocortin analog containing the sequence of formula (I).

26. Use of a non-naturally occurring melanocortin analogue for the prevention or reduction of symptoms associated with withdrawal from an addictive substance in a subject relative to a control, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (I).

27. The method or use of claim 25 or 26, wherein the symptoms associated with withdrawal from an addictive substance are selected from the group consisting of: pain, anxiety, depression, diarrhea, dizziness, fatigue, muscle pain, nausea, sleep problems, suicidal ideation, tremor, and visual impairment.

28. The method or use as described in any one of claims 1-27, wherein the subject is addicted to or prone to addiction to the addictive substance.

29. The method or use as described in any one of claims 1-28, wherein the subject has used or is using one or more addictive substances.

30. The method or use as described in any one of claims 5-29, wherein the addictive substance includes prescription drugs, substances contained in over-the-counter drugs, recreational substances, or illicit substances.

31. The method or use according to any one of claims 5-30, wherein the addictive substance is selected from the group consisting of: opioids, analgesics, stimulants, anesthetics, alcohol, sedatives, cannabis, cannabis derivatives, tetrahydrocannabinol (THC), cannabidiol (CBD), and inhalants.

32. The method or use of claim 31, wherein the opioid substance is selected from the group consisting of morphine, heroin, codeine, oxycodone, hydrocodone, and fentanyl.

33. The method or use of claim 31, wherein the stimulant is selected from the group consisting of caffeine, nicotine, methamphetamine, cocaine, and amphetamine.

34. The method or use of claim 31, wherein the sedative comprises a barbiturate or a benzodiazepine.

35. The method or use of claim 34, wherein the barbiturate is selected from the group consisting of phenobarbital, mesobarbital, buprofen, pentobarbital, primidone, and amobarbital.

36. The method or use of claim 34, wherein the benzodiazepine is selected from the group consisting of alprazolam, lorazepam, clonazepam, diazepam, and temazepam.

37. The method or use of claim 31, wherein the sedative is selected from the group consisting of: tranquilizers, xylazine, eszopiclone, zaleplon, zolpidem, and zopiclone.

38. The method or use of claim 31, wherein the inhalant is selected from the group consisting of: aerosols, butane, Freon, helium, nitrous oxide, propane, and nitrites.

39. The method or use of claim 33, wherein the nicotine comprises chewing tobacco, nicotine pouches, or smoking devices.

40. The method or use of claim 39, wherein the smoking device is selected from the group consisting of cigarettes, electronic cigarettes, cigars, and electronic cigarette products.

41. The method or use as claimed in any one of claims 1-40, wherein the control group comprises the subject prior to administration of the non-naturally occurring melanocortin analogue.

42. The method or use of any one of claims 1-41, wherein the control comprises the subject at baseline.

43. The method or use according to any one of claims 1-42, wherein the non-naturally occurring melanocortin analogue is a melanocortin 4 receptor (MC4R) agonist.

44. The method or use of claim 43, wherein the MC4R agonist is a full-type MC4R agonist.

45. The method or use of claim 43, wherein the MC4R agonist is a partial MC4R agonist.

46. ​​The method or use as described in any one of claims 1-45, wherein the non-naturally occurring melanocortin analogue is an MC3R antagonist.

47. The method or use of claim 46, wherein the MC3R antagonist is a complete MC3R antagonist.

48. The method or use of claim 46, wherein the MC3R antagonist is a partial MC3R antagonist.

49. The method or use as described in any one of claims 1-45, wherein the non-naturally occurring melanocortin analogue does not have MC3R activity.

50. The method or use according to any one of claims 1-49, wherein the non-naturally occurring melanocortin analog comprises a sequence according to formula (I), wherein: X 1 The group consisting of the following is not present or selected: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X 2 The following are not present: phenylalanine (Phe) or Nle; X 3 For non-existent, Phe, or Nle; R 1 Select from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R 2 Select from the following groups: Asp, proline (Pro), D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, dAla, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R 3 The following groups are not present or are selected: His, Ala, Pro, hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), 4-amino-1,4,5,6-tetrahydrozazaza-[4,3] -b Indole-3 ( 2H )-ketone (Aia), 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), 1-amino-4-phenylcyclohexane-carboxylic acid (APC), 4-aminophenylpiperidine-4-carboxylic acid (APPC), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexane-carboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), indolin-2-carboxylic acid (Ioc), 1-amino-1-cyclopentane-carboxylic acid (Cpe), and biphenylalanine (Bip); R 4 Select from the following groups: Phe, dPhe, 2'-D-naphthylalanine (dNal(2')), p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe) and p-fluoro-D-phenylalanine (p(F)dPhe); R 5 Choose from the following groups: Arg, His, cis Pro(guan), and trans Pro(guan); R 6 Select the following groups: Trp, dTrp, Phe, Aia, Aba, Ata, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 The group consisting of the following is not present or is selected: valine (Val), D-valine (dVal), β-valine. 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; Y 5 It is either non-existent or dVal; Y 6 It is either non-existent or dVal; Y 7 If it does not exist or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 1 Or R 2 and R 7 or R 8 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 1 or R 2 With R 7 Or R 8 disulfide bonds between them; When R 2 For Cys, R 7 For Pen and R 3 When R does not exist 2 With R 7 disulfide bonds between them; When R 1 Or R 2 For Asp and R 7 or R 8 When R is Lys or Orn 1 Or R 2 With R 7 Or R 8 The lactam bridge between them; and When R 2 For dAsp and R 7 When R is dLys 2 With R 7 The lactam bridge between them; The prerequisite is that the non-naturally occurring melanocortin analogue does not contain sequences selected from the group consisting of: Ac-Nle-c[Asp-Pro-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 194); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 5); Ac-Nle-c[Asp-Pro-His-dNal(2')-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 10); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro (SEQ ID NO: 2); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 3); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 4); Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 6); Ac-Nle-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 7); Ac-Nle-c[Asp-Hyp-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 9); Ac-Nle-Phe-Phe-c[Asp-Phe-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 12); Ac-dArg-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 15); Ac-dLeu-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 18); Ac-dAla-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 20); Ac-Ala-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 21); Ac-dNle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 24); Ac-dCys-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 28); Ac-dPhe-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 29); Ac-dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 30); dTyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 35); Tyr-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 36); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 40); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 41); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 42); Ac-Nle-c[dCys-Pro-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 43); Ac-Nle-c[Cys-Pro-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 48); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 54); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 64); Ac-Nle-c[Asp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 68); Ac-Nle-c[Asp-Ala-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 69); Ac-Nle-c[Asp-Leu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 76); Ac-Nle-c[Asp-Trp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 82); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 115); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 116); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 117); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 118); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 119); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-Hyp-NH2 (SEQ ID NO: 120); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-dHyp-NH2 (SEQ ID NO: 121); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-dVal-NH2 (SEQ ID NO: 122); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-dVal-NH2 (SEQ ID NO: 123); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-Val-NH2 (SEQ ID NO: 124); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-Val-NH2 (SEQ ID NO: 125); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-NH2 (SEQ ID NO: 126); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-NH2 (SEQ ID NO: 127); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-NH2 (SEQ ID NO: 128); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-NH2 (SEQ ID NO: 129); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 130); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 131); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-NH2 (SEQ ID NO: 132); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-NH2 (SEQ ID NO: 133); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 134); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 135); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 136); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 137); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 138); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 139); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 140); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 143); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 144); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 145); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-NH2 (SEQ ID NO: 146); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 147); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-dPro-NH2 (SEQ ID NO: 148); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 149); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 150); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 151); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 152); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 153); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 154); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 155); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 156); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 157); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 158); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-dVal-NH2 (SEQ ID NO:159); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 160); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 161); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 162); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO:164); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 165); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dPro-dVal-NH2 (SEQ ID NO: 166); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dPro-dVal-NH2 (SEQ ID NO:167); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 168); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Arg-dVal-dPro-NH2 (SEQ ID NO: 169); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO:170); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-dPro-NH2 (SEQ ID NO:171); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 172); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dVal-NH2 (SEQ ID NO: 173); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-NH2 (SEQ ID NO: 174); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO:175); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:176); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dTle-NH2 (SEQ ID NO: 177); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO: 178); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO:179); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:180); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:181); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO:182); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 183); Ac-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 184); Ac-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:185); Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ IDNO: 186); Ac-Nle-c[Asp-Trp-Pro-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 195); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 196); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 203); Ac-Nle-c[Asp-Aba-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 204); Ac-Nle-c[Asp-Aia-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 205); Ac-Nle-c[Asp-Ata-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 206); Ac-Nle-c[Asp-Cpe-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 240); Ac-Nle-c[Asp-Che-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 241); Ac-Nle-c[Asp-Oic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 242); Ac-Nle-c[Asp-Tic-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 244); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 245); Ac-Nle-c[Asp-His-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:247); Ac-Nle-c[Asp-His-dNal(2')-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:248); Ac-Nle-c[Asp-Pro-dNal(2')-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:250); Ac-Nle-c[Asp-Pro-dNal(2')-cis-Pro(guan)Pro-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 251); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 253); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 254); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 255); Ac-Nle-c[Asp-Glu-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 256); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 259); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ IDNO: 260); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ IDNO: 261); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Trp-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO:263); Ac-Nle-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 273); Ac-Arg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 274); Ac-dArg-c[Asp-Ala-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:275); Ac-dLeu-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 327); Ac-dNle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 328); Ac-dArg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 329); Ac-Arg-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 330); Ac-dPhe-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 331); Ac-dTyr-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 332); Ac-Ala-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 333); Ac-dHis-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 334); Ac-His-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 335); Ac-dLys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 336); Ac-Lys-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 337); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dVal-dPro-NH2 (SEQ ID NO:344); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dVal-dPro-NH2 (SEQ ID NO:345); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dArg-dPro-NH2 (SEQ ID NO: 346); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dLys-dPro-NH2 (SEQ ID NO: 347); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dVal-dHyp-NH2 (SEQ ID NO: 348); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-dPen]-dTle-dPro-NH2 (SEQ ID NO: 349); Ac-Nle-c[dPen-Pro-dNal(2')-Arg-Trp-Gly-dPen]-dVal-dPro-NH2 (SEQ ID NO:350); Ac-Nle-c[Asp-Pro-dNal(2')-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 103); Ac-Nle-c[Asp-Ioc-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 243); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 44); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 45); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 46); Ac-Nle-c[dCys-dNal(2')-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 47); Ac-Nle-c[Cys-dNal(2')-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 56); Ac-Nle-c[dPen-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 62); Ac-Nle-c[Asp-dTrp-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 83); Ac-Nle-c[dPen-Ala-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 338); Ac-Nle-c[dPen-Leu-dNal(2')-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 339); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:473); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Gln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 491); Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:471); Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545); Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:547); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:548); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:549); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:551); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-dHis-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 562); Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569); Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571); Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621); Ac-Nle-c[Asp-His-dPhe-trans-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 228); Ac-Nle-c[Asp-His-dPhe-cis-Pro(guan)-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 229); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 431); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Pro-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 297); Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531); Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:509); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:510); Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:516); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); Ac-Nle-c[Asp-dGln-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 530); Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 268); Ac-Nle-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 378); Ac-dArg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 379); Ac-Nle-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:266); Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:267); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO:269); Ac-dArg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:270); Ac-Arg-c[Cys-dAla-His-dNal(2')-Arg-Trp-Cys]-NH2 (SEQ ID NO: 282); and Ac-Arg-c[Asp-dAla-His-dNal(2')-Arg-Trp-Lys]-NH2 (SEQ ID NO: 283).

51. The method or use according to any one of claims 1-49, wherein the non-naturally occurring melanocortin analog comprises the sequence according to formula (IA): X 1 -X 2 -X 3 -R 1 -R 2 -R 3 -R 4 -R 5 -R 6 -R 7 -R 8 -Y 1 -Y 2 -Y 3 -Y 4 (IA), in: X 1 The group consisting of the following is not present or selected: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis). X 2 The following are not present: phenylalanine (Phe) or Nle; X 3 For non-existent, Phe, or Nle; R 1 Select from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R 2 Select from the following groups: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R 3 The following groups are excluded or selected: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R 4 Select the group consisting of the following: dPhe, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R 5 For Arg or His; R 6 Select the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 Choose from the following groups: valine (Val), D-valine (dVal), β-valine (dVal), and β-valine (dVal). 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 1 Or R 2 and R 7 Or R 8 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 1 Or R 2 With R 7 Or R 8 disulfide bonds between them; When R 2 For Cys, R 7 For Pen and R 3 When R does not exist 2 With R 7 disulfide bonds between them; When R 1 Or R 2 For Asp and R 7 Or R 8 When R is Lys or Orn 1 Or R 2 With R 7 Or R 8 The lactam bridge between them; and When R 2 For dAsp and R 7 When R is dLys 2 With R 7 The lactam bridge between them; The premise is: When R 4 When p(F)dPhe, then (i) R 3 Selected from Pro, dGln, dTyr, R 6 For Trp, and the non-naturally occurring melanocortin analogue is not in R. 2 Cys and R at the location 7 Cys are cyclic at the location; or (ii) R 3 For His, and either R 6 For Nal(2'), or the non-naturally occurring melanocortin analogue via R 2 With R 7 Disulfide bond cyclization between R 2 and R 7 same; When R 4 When the value is p(Br)dPhe, the non-natural melanocortin analogue is obtained through R. 2 dCys and R at the location 7 Disulfide bond cyclization between Cys or dCys at the site; When R 4 When dPhe is true, then (i) R 3 (ii) R 3 For His, and either R 2 For Phe or dAla, or R 2 For Ala and X 1 For Arg or dArg, (iii) R 3 For Pro and (a) R 2 For Trp, and R 5 Not His or R 6 Not for Phe or (b) R 2 Not Trp or Pro, and either R 5 It is not dNal(2') or Nal(2'), or X 1 and Y 3 They do not exist simultaneously, or (iv) R 3 For does not exist and R 2 and R 7 Not all are dPen; and When R 4 When p(Cl)dPhe is true, then (i) R 3 Selected from Aba, Aia, and Ata or (ii) R 3 For His, R 1 Not Ala, and (a) if R 1 For Nle and Y 1 Y 2 If it is dVal-dPro, then X 1 For non-existent and non-naturally occurring melanocortin analogues, via R 2 dCys and R at the location 7 Disulfide bond cyclization between dCsys at the location, or (b) if R 1 For Nle and Y 1 Y 2 If it is not dVal-dPro, then it is either X 1 Existence, or Y 3 exist.

52. The method or use according to any one of claims 1-50, wherein the non-naturally occurring melanocortin analog comprises a sequence according to formula (IA), wherein: X 1 The group consisting of the following is not present or selected: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis). X 2 The following are not present: phenylalanine (Phe) or Nle; X 3 For non-existent, Phe, or Nle; R 1 Select from the following groups: Nle, D-leucine (dNle), Ala, D-alanine (dAla), Arg, dArg, Lys, dLys, His, dHis, ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), D-tryptophan (dTrp), aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R 2 Select from the following groups: Asp, D-aspartic acid (dAsp), Cys, dCys, D-penicillamine (dPen), Ala, Trp, Phe, dPhe, His, dHis, Tyr, and dTyr; R 3 The following groups are excluded or selected: His, Ala, proline (Pro), hydroxyproline (Hyp), leucine (Leu), D-glutamine (dGln), Phe, dPhe, Trp, dTrp, Tyr, dTyr, 2-aminotetrahydronaphthalene-2-carboxylic acid (Atc), octahydroindole-2-carboxylic acid (Oic), 1-amino-1-cyclohexanecarboxylic acid (Che), tetrahydro-isoquinoline-3-carboxylic acid (Tic), 1-amino-1-cyclopentanecarboxylic acid (Cpe), and biphenylalanine (Bip); R 4 Select the group consisting of the following: dPhe, p-chloro-D-phenylalanine (p(Cl)dPhe), p-bromo-D-phenylalanine (p(Br)dPhe), and p-fluoro-D-phenylalanine (p(F)dPhe); R 5 For Arg or His; R 6 Select the following groups: Trp, dTrp, Phe, dNal(2'), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Pro, Lys, dLys, Cys, dCys, penicillamine (Pen), dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 Choose from the following groups: valine (Val), D-valine (dVal), β-valine (dVal), and β-valine (dVal). 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 1 Or R 2 and R 7 or R 8 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 1 or R 2 With R 7 Or R 8 disulfide bonds between them; When R 2 For Cys, R 7 For Pen and R 3 When R does not exist 2 With R 7 disulfide bonds between them; When R 1 or R 2 For Asp and R 7 or R 8 When R is Lys or Orn 1 or R 2 With R 7 or R 8 The lactam bridge between them; and When R 2 For dAsp and R 7 When R is dLys 2 With R 7 The lactam bridge between them; The prerequisite is that the non-naturally occurring melanocortin analogue does not contain sequences selected from the group consisting of: Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 223); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 464); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 465); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 466); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 467); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 468); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 469); Ac-Nle-c[Asp-His-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 470); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:474); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:475); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 476); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 477); Ac-Nle-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:478); Ac-Arg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 481); Ac-Lys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 482); Ac-dLys-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 483); Ac-His-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 484); Ac-dHis-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 485); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 463); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 462); Ac-Ala-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 479); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:473); Ac-dArg-c[Asp-His-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 480); Ac-Nle-c[Asp-Bip-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 489); Ac-Nle-c[Asp-Trp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 493); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:444); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 445); Ac-Nle-c[Asp-Tyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 495); Ac-Nle-c[Asp-Phe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 487); Ac-Nle-c[Asp-dPhe-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 488); Ac-Nle-c[Asp-dTrp-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 494); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:471); Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[Asp-Pro-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 217); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 222); Ac-Nle-c[Cys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 535); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 538); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:545); Ac-Nle-c[Asp-His-p(Br)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 546); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:547); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:548); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:549); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:551); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 552); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:553); Ac-Ala-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 555); Ac-Nle-c[Asp-Phe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 563); Ac-Nle-c[Asp-dPhe-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 564); Ac-Nle-c[Asp-Bip-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 565); Ac-Nle-c[Asp-dGln-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 568); Ac-Nle-c[Asp-Trp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 569); Ac-Nle-c[Asp-dTrp-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 570); Ac-Nle-c[Asp-Tyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 571); Ac-Nle-c[Asp-dTyr-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 572); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 539); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 544); Ac-dHis-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 561); Ac-dArg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 556); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 542); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 560); Ac-His-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 543); Ac-dLys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 559); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 557); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 541); Ac-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 550); Ac-Lys-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 558); Ac-Arg-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 540); Ac-Nle-Nle-c[Asp-His-p(Br)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:554); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 363); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 418); Ac-Nle-c[Asp-His-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 621); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:639); Ac-Nle-c[dPen-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 326); Ac-Nle-c[Asp-Trp-Pro-dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 398); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 401); Ac-Nle-c[Asp-Pro-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 225); Ac-Nle-c[Asp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 430); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 431); Ac-Nle-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 380); Ac-Nle-c[Asp-Pro-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 215); Ac-Nle-c[Asp-Phe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 525); Ac-Nle-c[Asp-dPhe-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 526); Ac-Nle-c[Asp-Bip-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 527); Ac-Nle-c[Asp-Trp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 531); Ac-Nle-c[Asp-Tyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 533); Ac-Nle-c[Asp-dTyr-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 534); Ac-Nle-c[Asp-dTrp-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 532); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 498); Ac-Nle-c[Cys-His-p(Cl)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 497); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:509); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:510); Ac-Nle-c[Asp-His-p(Cl)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 508); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 517); Ac-Ala-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 500); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); and Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514).

53. The method or use as described in any one of claims 1-49, wherein the non-naturally occurring melanocortin analogue includes the sequence of formula (IB): X 1 -X 2 -X 3 -R 1 -R 2 -Pro-R 4 -R 5 -R 6 -R 7 -R 8 -Y 1 -Y 2 -Y 3 -Y 4 -Y 5 -Y 6 -Y 7 (IB), in: X 1 It is either absent or contains no leucine (Nle). X 2 It is either non-existent or Nle; X 3 It is either non-existent or Nle; R 1 Select groups composed of the following: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R 2 Select the group consisting of the following: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R 4 It is either dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R 5 Choose from the following groups: Arg, His, cis Pro(guan), and trans Pro(guan); R 6 Select from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 The group consisting of the following is not present or is selected: valine (Val), D-valine (dVal), β-valine. 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; Y 5 It is either non-existent or dVal; Y 6 It is either non-existent or dVal; Y 7 If it does not exist or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 2 and R 7 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 2 With R 7 disulfide bonds between; and When R 2 For Asp or dAsp and R 7 When R is Lys, dLys, or Orn 2 With R 7 The lactam bridge between them; The premise is: When R 4 When p(F)dPhe is present, the non-natural melanocortin analogue is not in R. 2 Cys and R at the location 7 Cys are cyclic at the points; and When R 4 For dPhe and X 1 X 2 and X 3 When one or more of them exist, then Y 3 -Y 7 It does not exist.

54. The method or use according to any one of claims 1-50, wherein the non-naturally occurring melanocortin analogue includes the sequence of formula (IB), wherein: X 1 -X 2 -X 3 -R 1 -R 2 -Pro-R 4 -R 5 -R 6 -R 7 -R 8 -Y 1 -Y 2 -Y 3 -Y 4 -Y 5 -Y 6 -Y 7 (IB), in: X 1 It is either absent or contains no leucine (Nle). X 2 It is either non-existent or Nle; X 3 It is either non-existent or Nle; R 1 Select groups composed of the following: Nle, D-leucine (dNle), alanine (Ala), D-alanine (dAla), arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), D-histidine (dHis), ornithine (Orn), D-ornithine (dOrn), D-leucine (dLeu), D-tyrosine (dTyr), phenylalanine (Phe), D-phenylalanine (dPhe), tryptophan (Trp), and D-tryptophan (dTrp); R 2 Select the group consisting of the following: aspartic acid (Asp), D-aspartic acid (dAsp), cysteine ​​(Cys), D-cysteine ​​(dCys), and D-penicillamine (dPen); R 4 It is either dPhe or p-fluoro-D-phenylalanine (p(F)dPhe); R 5 Choose from the following groups: Arg, His, cis Pro(guan), and trans Pro(guan); R 6 Select from the following groups: Trp, dTrp, Phe, Aia, Aba, Ata and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Gly, Lys, dLys, Cys, dCys, dPen, and Orn; R 8 If it does not exist or is Lys; Y 1 The group consisting of the following is not present or is selected: valine (Val), D-valine (dVal), β-valine. 2 -valine (β) 2 -Val), β 3 -valine (β) 3 -Val), Pro, D-proline (dPro), β-proline (β-Pro), Hyp, D-hydroxyproline (dHyp), D-tert-leucine (dTle), dLeu, Trp, Arg, dArg, Lys, dLys, Gly, Ala, dAla, Asp, dAsp, Asparagine (Asn), D-asparagine (dAsn), and D-threonine (dThr); Y 2 For non-existent or selected from the following groups: Val, dVal, β 2 -Val、β 3 -Val, Pro, dPro, β-Pro, Hyp, dHyp, dTle, Arg, dArg, Gly, Ala, dAla, Asp and dAsn; Y 3 For non-existent groups or groups consisting of the following: Val, dVal, Pro, dPro, dThr, Lys, and dLys; Y 4 For non-existent groups or groups consisting of the following: dVal, dPro, Asp, and dAsp; Y 5 It is either non-existent or dVal; Y 6 It is either non-existent or dVal; Y 7 It is either non-existent or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 2 and R 7 When each of the elements in R is independently selected from the group consisting of Cys, dCys, and dPen, 2 With R 7 disulfide bonds between; and When R 2 For Asp or dAsp and R 7 When R is Lys, dLys, or Orn 2 With R 7 The lactam bridge between them; Provided that the non-naturally occurring melanocortin analogue does not contain the following sequence: Ac-Nle-c[Cys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 432); or Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 639).

55. The method or use as described in any one of claims 1-49, wherein the non-naturally occurring melanocortin analogue comprises the sequence of formula (IC): X 1 -X 2 -R 1 -R 2 -Pro-dPhe-R 5 -R 6 -R 7 -Y 1 -Y 2 -Y 3 -Y 4 (IC), in: X 1 Select the group consisting of the following: leucine (Nle), arginine (Arg), D-arginine (dArg), alanine (Ala), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); X 2 It is either non-existent or Nle; R 1 Choose from the following groups: aspartic acid (Asp), cysteine ​​(Cys), and D-cysteine ​​(dCys); R 2 Select from the following groups: tryptophan (Trp), phenylalanine (Phe), D-phenylalanine (dPhe), histidine (His), D-histidine (dHis), tyrosine (Tyr), and D-tyrosine (dTyr). R 5 For Arg; R 6 Select the following groups: Trp, 2'-D-naphthylalanine (dNal(2')), 2'-naphthylalanine (Nal(2')) and 1'-naphthylalanine (Nal(1')); R 7 Choose from the following groups: Lys, Cys, and dCys; Y 1 The group consisting of the following is absent or selected: D-valine (dVal), D-tert-leucine (dTle), dArg, and dLys; Y 2 The group that is absent or selected from the following groups: dVal, dPro, and D-hydroxyproline (dHyp); Y 3 For non-existent, dVal, or dPro; Y 4 It is either non-existent or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 1 and R 7 When R is independently selected from the groups composed of Cys, dCys, and dPen, 1 With R 7 disulfide bonds between them; as well as When R 1 For Asp and R 7 When R is Lys 1 With R 7 The lactam bridge between them.

56. The method or use as described in any one of claims 1-49, wherein the non-naturally occurring melanocortin analogue includes the sequence of formula (ID): X 1 -R 1 -R 2 -R 3 -p(Cl)dPhe-Arg-Trp-R 7 -Y 1 -Y 2 -Y 3 -Y 4 (ID), in: X 1 It is either absent or contains no leucine (Nle). R 1 Select the group consisting of the following: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R 2 It is either aspartic acid (Asp) or D-cysteine ​​(dCys); R 3 The following groups were selected: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), and 4-amino-1,4,5,6-tetrahydrozazaza[4,3] -b Indole-3 ( 2H )-ketone (Aia); R 7 For Lys or dCys; Y 1 Select from the following groups: D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y 2 For non-existent or selected from the following groups: dVal, dPro, and dTle; Y 3 For non-existent, dVal, or dPro; Y 4 It is either non-existent or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 2 and R 7 When both are dCys, R 2 With R 7 disulfide bonds between; and When R 2 For Asp and R 7 When R is Lys 2 With R 7 The lactam bridge between them; The premise is that when R 3 For His and R 1 When Nle, then (i) Y 1 Y 2 For dVal-dPro, X 1 It does not exist, and the non-naturally occurring melanocortin analogue is cyclized via disulfide bonds, or (b) Y 1 Y 2 Not for dVal-dPro and either X 1 Existence, or Y 3 exist.

57. The method or use according to any one of claims 1-50, wherein the non-naturally occurring melanocortin analogue includes the sequence of formula (ID), wherein: X 1 It is either absent or contains no leucine (Nle). R 1 Select the group consisting of the following: Nle, arginine (Arg), D-arginine (dArg), lysine (Lys), D-lysine (dLys), histidine (His), and D-histidine (dHis); R 2 It is either aspartic acid (Asp) or D-cysteine ​​(dCys); R 3 The following groups were selected: His, 4-amino-1,2,4,5-tetrahydro-2-benzozaza-3-one (Aba), 7-amino-7,8-dihydro-4H-[1,2,3]triazolo-[1,5-a][1,4]diaza-6(5H)-one (Ata), and 4-amino-1,4,5,6-tetrahydrozazaza[4,3] -b Indole-3 ( 2H )-ketone (Aia); R 7 For Lys or dCys; Y 1 Select from the following groups: D-valine (dVal), D-proline (dPro), and D-tert-leucine (dTle); Y 2 For non-existent or selected from the following groups: dVal, dPro, and dTle; Y 3 For non-existent, dVal, or dPro; Y 4 It is either non-existent or dPro; and The non-natural melanocortin analogues are partially cyclized by selecting from the group consisting of: When R 2 and R 7 When both are dCys, R 2 With R 7 disulfide bonds between; and When R 2 For Asp and R 7 When R is Lys 2 With R 7 The lactam bridge between them; The prerequisite is that the non-naturally occurring melanocortin analogue does not contain sequences selected from the group consisting of: Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 220); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:507); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 516); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 514); and.

58. The method or use as described in any one of claims 1-57, wherein the N-terminus of the non-naturally occurring melanocortin analog is modified with an acyl group.

59. The method or use of claim 58, wherein the acyl group is an acetyl group.

60. The method or use as described in any one of claims 1-57, wherein the N-terminus of the non-naturally occurring melanocortin analogue is not modified.

61. The method or use according to any one of claims 1-60, wherein the C-terminus of the non-naturally occurring melanocortin analog is modified with an amide group.

62. The method or use as described in any one of claims 1-60, wherein the C-terminus of the non-naturally occurring melanocortin analogue is not modified.

63. The method or use according to any one of claims 1-67, wherein Y 1 -Y 2 It exists, and Y 3 -Y 8 It does not exist.

64. The method or use as claimed in any one of claims 1-63, wherein Y 1 It is D-valine, and Y 2 It is D-proline.

65. The method or use as claimed in any one of claims 1-63, wherein Y 1 It is D-tert-leucine and Y 2 It is D-proline.

66. The method or use as claimed in any one of claims 1-62, wherein R 4 It is dNal(2').

67. The method or use as claimed in claim 66, wherein the sequence of formula (I) is: Ac-Nle- c [Asp-His-dNal(2')-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 8), where c represents the result of passing through R 2 and R 8 Cyclation via lactam bonds.

68. The method or use as claimed in any one of claims 1-62, wherein R 4 It is either Phe or dPhe.

69. The method or use as claimed in claim 68, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-OH (SEQ ID NO: 291); Ac-Nle-c[Asp-Pro-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 294); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 295; E2); and Ac-Nle-c[Asp-Pro-His-Phe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 296). Where c represents through R 2 and R 7 Cyclation via lactam bonds.

70. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-dLeu-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:298); Ac-dAla-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 299); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 300); Ac-dNle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 301); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 302); Ac-dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 303); Ac-dTyr-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 304); Phe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 305); His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 306); Trp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 307); dPhe-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 308); dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 309); dTrp-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 310); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 311); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 312); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 313); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 314); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 315); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 316); and Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 317), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

71. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Cys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 318); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 319); Ac-Nle-c[dPen-Pro-dPhe-Arg-Trp-dPen]-dVal-dPro-NH2 (SEQ ID NO: 320); Ac-Nle-c[dCys-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 321); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 322); and Ac-Nle-c[Cys-dPhe-Arg-Trp-Pen]-dVal-dPro-NH2 (SEQ ID NO: 324), Where c represents through R 2 and R 7 It is cyclized via an internal disulfide bond.

72. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dVal-dPro-NH2 (SEQ ID NO: 351); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-Lys-Asp-NH2 (SEQ ID NO: 352); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Gly-Lys]-dPro-dPro-dLys-dAsp-NH2 (SEQ ID NO:353), Where c represents through R 2 and R 8 Cyclation via lactam bonds.

73. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 354); Ac-Nle-c[Asp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 355); Ac-Nle-c[Asp-Cpe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 358); Ac-Nle-c[Asp-Che-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 359); Ac-Nle-c[Asp-Oic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 360); Ac-Nle-c[Asp-Ioc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 361); Ac-Nle-c[Asp-Tic-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 362); Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 364); Ac-Nle-c[Asp-Phe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 366); Ac-Nle-c[Asp-dPhe-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 367); Ac-Nle-c[Asp-Bip-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 368); Ac-Nle-c[Asp-dGln-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 371); Ac-Nle-c[Asp-Trp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 372); Ac-Nle-c[Asp-dTrp-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 373); Ac-Nle-c[Asp-Tyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 374); Ac-Nle-c[Asp-dTyr-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 375); Ac-Nle-c[Asp-Aba-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 198); Ac-Nle-c[Asp-Aia-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 207); Ac-Nle-c[Asp-Ata-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 208); Ac-Nle-c[Asp-Atc-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 212); Ac-Nle-c[Asp-APC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 213); and Ac-Nle-c[Asp-APPC-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 214), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

74. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-dAla-His-dPhe-Arg-Trp-Lys]-NH2 (SEQ ID NO: 281); Ac-Arg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 381); and Ac-dArg-c[Asp-Ala-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 382), Where c represents through R 1 and R 7 Cyclation via lactam bonds.

75. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 226); Ac-Nle-c[Cys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 383); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 384); Ac-Nle-c[dCys-Trp-Pro-dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 385); Ac-Ala-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 386); Ac-Lys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 387); Ac-dLys-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 388); Ac-Arg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 389); Ac-dArg-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 390); Ac-dHis-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 391); Ac-His-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 392); Ac-Nle-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 393); Ac-Nle-c[Asp-Trp-Ala-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 394); Ac-Nle-c[Asp-Trp-Leu-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 395); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(1']-Lys]-dVal-dPro-NH2 (SEQ ID NO: 399); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-dNal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO:403); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Nal(2’)-Lys]-dVal-dPro-NH2 (SEQ ID NO: 404); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO:405); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO:406); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 407); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 408); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 409); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 410); Ac-Nle-c[Asp-Trp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO: 411); Ac-Nle-c[Asp-Phe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 412); Ac-Nle-c[Asp-His-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 413); Ac-Nle-c[Asp-Tyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 414); Ac-Nle-c[Asp-dPhe-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 415); Ac-Nle-c[Asp-dHis-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 416); and Ac-Nle-c[Asp-dTyr-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 417), Where c represents through R 1 and R 7 Cycling via lactam bonds or disulfide bonds.

76. The method or use as claimed in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is: Ac-Nle-c[Asp-Hyp-dPhe-Arg-Trp-Pro-Lys]-dVal-dPro-NH2 (SEQ ID NO: 419), where c represents through R 2 and R 8 Cyclation via lactam bonds.

77. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Phe-Phe-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 421); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dLeu-dPro-NH2 (SEQ ID NO: 422); Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 423); and Ac-Nle-c[Asp-Phe-His-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 424), Where c represents through R 1 and R 7 Cyclation via lactam bonds.

78. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-dTrp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 187); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aia-Lys]-dVal-dPro-NH2 (SEQ ID NO: 233); Ac-Nle-c[Asp-Pro-dPhe-Arg-Aba-Lys]-dVal-dPro-NH2 (SEQ ID NO: 234); Ac-Nle-c[Asp-Pro-dPhe-Arg-Ata-Lys]-dVal-dPro-NH2 (SEQ ID NO: 235); Ac-Nle-c[Asp-Pro-dPhe-Arg-Nal(1')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 427); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Phe-Lys]-dVal-dPro-NH2 (SEQ ID NO: 429), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

79. The method or use as claimed in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 218); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 433); Ac-Nle-c[dCys-Pro-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 434); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 435); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 436); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 437); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 438); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 439); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 440); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 441); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 442); Ac-Nle-c[Asp-Pro-p(F)dPhe-His-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 443); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO:446); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:447); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:448); Ac-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 449); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 450); Ac-Nle-Nle-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:451); Ac-Ala-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 452); Ac-dArg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 453); Ac-Arg-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 454); Ac-Lys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 455); Ac-dLys-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 456); Ac-His-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 457); Ac-dHis-c[Asp-Pro-p(F)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 458); Ac-Nle-c[Cys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 459); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 460); Ac-Nle-c[dCys-His-p(F)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 461); Ac-Nle-c[Asp-His-p(F)dPhe-Arg-Nal(2')-Lys]-dVal-dPro-NH2 (SEQ ID NO: 472); Ac-Nle-c[Asp-dGln-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 492); and Ac-Nle-c[Asp-dTyr-p(F)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 496), Where c represents through R 2 and R 7 Cycling via lactam bonds or disulfide bonds.

80. The method or use as claimed in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Aba-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 209); Ac-Nle-c[Asp-Aia-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 210); Ac-Nle-c[Asp-Ata-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 211); Ac-Nle-c[dCys-His-p(Cl)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 499); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 501); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 502); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 503); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 504); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 505); Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 506); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 511); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ IDNO: 512); Ac-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO:513); Ac-Nle-Nle-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO:515); Ac-dArg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 518); Ac-Arg-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 519); Ac-Lys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 520); Ac-dLys-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 521); Ac-His-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 522); and Ac-dHis-c[Asp-His-p(Cl)dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 523), Where c represents through R 2 and R 7 Cycling via lactam bonds or disulfide bonds.

81. The method or use as claimed in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-Cys]-dVal-dPro-NH2 (SEQ ID NO: 536); or Ac-Nle-c[dCys-His-p(Br)dPhe-Arg-Trp-dCys]-dVal-dPro-NH2 (SEQ ID NO: 537), Where c represents through R 2 and R 7 It is cyclized via an internal disulfide bond.

82. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-Pro-NH2 (SEQ ID NO: 573); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Hyp-NH2 (SEQ ID NO: 574); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 575); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Val-NH2 (SEQ ID NO: 576); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Pro-NH2 (SEQ ID NO: 577); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Arg-NH2 (SEQ ID NO: 578); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dArg-NH2 (SEQ ID NO: 579); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 580); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-NH2 (SEQ ID NO: 581); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-NH2 (SEQ ID NO: 582); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Pro-Val-NH2 (SEQ ID NO: 583); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 584); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-Val-Pro-NH2 (SEQ ID NO: 585); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dVal-dPro-NH2 (SEQ ID NO: 586); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 587); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Pro-Val-NH2 (SEQ ID NO: 588); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Arg-Val-Pro-NH2 (SEQ ID NO: 589); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 590); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 591); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dPro-NH2 (SEQ ID NO: 592); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dTle-dVal-NH2 (SEQ ID NO: 593); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dTle-NH2 (SEQ ID NO: 594); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dPro-NH2 (SEQ ID NO: 595); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-dPro-NH2 (SEQ ID NO: 596); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:597); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-dVal-dPro-NH2 (SEQ ID NO:598); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dVal-dVal-dVal-dPro-NH2(SEQ ID NO: 599); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Trp-NH2 (SEQ ID NO: 600); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-dVal-NH2 (SEQ ID NO: 601); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAla-dAla-NH2 (SEQ ID NO: 602); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-NH2 (SEQ ID NO: 603); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dHyp-NH2 (SEQ ID NO: 604); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dAsn-NH2 (SEQ ID NO: 605); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-Asp-NH2 (SEQ ID NO: 606); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-dPro-NH2 (SEQ ID NO: 607); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Hyp-NH2 (SEQ ID NO: 608); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Ala-Ala-NH2 (SEQ ID NO: 609); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Gly-Gly-NH2 (SEQ ID NO: 610); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asp-dPro-NH2 (SEQ ID NO: 611); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-dPro-NH2 (SEQ ID NO: 612); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Asn-NH2 (SEQ ID NO: 613); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsp-NH2 (SEQ ID NO: 614); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dAsn-NH2 (SEQ ID NO: 615); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-Lys-dPro-NH2 (SEQ ID NO: 616); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-OH (SEQ ID NO: 617); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-NH2 (SEQ ID NO: 618); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dThr-dPro-dThr-OH (SEQ ID NO: 619); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dPro-dVal-NH2 (SEQ ID NO: 620); Ac-Nle-c[dAsp-Pro-dPhe-Arg-Trp-dLys]-dPro-dVal-NH2 (SEQ ID NO: 622); Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β 2 Val-NH2 (SEQ ID NO: 623)? Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-β 3 Val-NH2 (SEQ ID NO: 624)? Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β 2 Val-βPro-NH2 (SEQ ID NO: 625)? Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-β 3 Val-βPro-NH2 (SEQ ID NO: 626); and Ac-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-βPro-βPro-NH2 (SEQ ID NO: 627), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

83. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 628); Ac-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO: 629); and Ac-Nle-Nle-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dPro-NH2 (SEQ ID NO:630), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

84. The method or use as described in any one of claims 1-62, wherein the sequence of any one of formulas (I)-(ID) is selected from the group consisting of: Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dVal-dPro-NH2 (SEQ ID NO: 631); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dVal-dPro-NH2 (SEQ ID NO: 632); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dArg-dPro-NH2 (SEQ ID NO: 633); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dLys-dPro-NH2 (SEQ ID NO: 634); Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dHyp-NH2 (SEQ ID NO: 635); Ac-Orn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 636); Ac-dOrn-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dVal-dVal-dVal-dPro-NH2 (SEQ ID NO:637); Ac-Nle-Nle-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 638); Ac-Ala-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 640); Ac-dArg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 641); Ac-Arg-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 642); Ac-Lys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 643); Ac-dLys-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 644); Ac-His-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 645); and Ac-dHis-c[Asp-Pro-dPhe-Arg-Trp-Lys]-dTle-dPro-NH2 (SEQ ID NO: 646), Where c represents through R 2 and R 7 Cyclation via lactam bonds.

85. The method or use according to any one of claims 1-57, wherein the non-naturally occurring melanocortin analog comprises SEQ ID NO: Any one of the following: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646.

86. The method or use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NO: 187, 212, 218, 226, 291, 295, 298-322, 324, 351-355, 358-360, 362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-598, 600-646.

87. The method or use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NO: 187, 218, 231-235, 291, 295, 298-322, 351-353, 425, 427, 429, 433-443, 446-458, 573-599, 600-620, 622-646.

88. The method or use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NO: 226, 383-393, 399, 403-417.

89. The method or use of claim 85, wherein the non-naturally occurring melanocortin analog comprises any one of the sequences of SEQ ID NO: 209-211, 499, 501-506, 511-513, 515, 518-523.

90. The method or use according to any one of claims 1-89, wherein the non-naturally occurring melanocortin analogue is present in the pharmaceutical composition.

91. The method or use of claim 90, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients and / or carriers.

92. The method or use of claim 91, wherein the one or more pharmaceutically acceptable excipients and / or carriers of the pharmaceutical composition comprise water.

93. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered as follows: (i) once daily at a first dose of about 5 mg / kg to about 20 mg / kg for about 5 days to about 10 days; (ii) once daily at a second dose of about 10 mg / kg to about 40 mg / kg after administration of the first dose for about 5 days to about 10 days; (iii) twice daily at a third dose of about 5 mg / kg to about 30 mg / kg after administration of the second dose for at least about 5 days to about 10 days.

94. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered as follows: (i) once a day at a first dose of about 5 mg / kg for about 7 days; (ii) once a day at a second dose of about 15 mg / kg after the administration of the first dose for about 7 days; and (iii) twice a day at a third dose of about 10 mg / kg after the administration of the second dose for at least about 7 days.

95. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered as follows: (i) once a day at a first dose of about 10 mg / kg for about 7 days; (ii) once a day at a second dose of about 20 mg / kg after the administration of the first dose for about 7 days; and (iii) twice a day at a third dose of about 15 mg / kg after the administration of the second dose for at least about 7 days.

96. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered as follows: (i) once a day at a first dose of about 15 mg / kg for about 7 days; (ii) once a day at a second dose of about 25 mg / kg after the administration of the first dose for about 7 days; and (iii) twice a day at a third dose of about 20 mg / kg after the administration of the second dose for at least about 7 days.

97. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered once daily at a dose of about 0.5 mg / kg to about 10 mg / kg based on the subject's body weight.

98. The method or use of claim 97, wherein the non-naturally occurring melanocortin analogue is administered once daily at a dose of about 1 mg / kg or 3 mg / kg based on the subject's body weight.

99. The method or use according to any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered once daily at a dose of about 0.1 mg to about 100 mg.

100. The method or use as described in any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered once daily at a dose of about 10 mg or about 50 mg.

101. The method or use as described in any one of claims 1-100, wherein the non-naturally occurring melanocorticoid analogue is administered via intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intravenous, intranasal, or oral administration.

102. The method or use as described in any one of claims 1-101, wherein the non-naturally occurring melanocortin analog crosses the blood-brain barrier of the subject.

103. The method or use as described in any one of claims 101 or 102, wherein the non-naturally occurring melanocortin analog comprises SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646, any one of the sequences and administered at a dose of 0.001 mg / kg to 25 mg / kg based on the subject's body weight. Administer at least once daily at doses within the mg / kg range.

104. The method or use of claim 103, wherein the non-naturally occurring melanocortin analog comprises SEQ ID NO: 8, 187, 198, 207-218, 226, 231-235, 281, 291, 294-296, 298-322, 324, 351-355, 358-362, 364, 366-368, 371-375, 381-395, 399, 403-417, 419, 421-425, 427, 429, 433-443, 446-461, 472, 492, 496, 499-506, 511-513, 515, 518-523, 536-537, 573-599, 600-620, 622-646, any one of the sequences and administered at a dose of 0.5 mg / kg to 10 mg / kg based on the subject's body weight. Administer at least once daily at doses within the mg / kg range.

105. The method or use as described in any one of claims 1-92, wherein the non-naturally occurring melanocortin analogue is administered to a subject for at least 1 day, 1 week, 1 month, 3 months, 6 months, 1 year, or 5 years.

106. The method or use as described in any one of claims 1-104, wherein the non-naturally occurring melanocortin analogue is administered to a subject for 1 day, 5 days, 7 days, 14 days, 21 days, 28 days, 35 days, 40 days, 45 days, 50 days, 60 days, 75 days, 90 days, 100 days, 110 days, or 120 days.

Images